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Chapter 1  
Introduction 
1.1 Cancer and the immune system 
 Cancer is now the second leading cause of death in the United States.1 In 2018 
alone, 1,735,350 new patients are expected be diagnosed with cancer resulting in 
609,640 deaths in the United States.1 Furthermore, cancer diagnoses are expected to 
double by 2030.2 The toll of cancer is not only felt through the number of lives lost but 
also by the significant economic impact. The estimated financial burden of cancer in the 
United States in 2014 was $87.6 billion alone.2 While these numbers are troubling, a 
significant amount of process has been made in combating this deadly disease since 
President Nixon’s infamous declaration of a national “War on cancer” in 1971 by signing 
the National cancer act. Indeed, the annual death rate attributed to cancer has been 
steadily declining the past 2 decades and has dropped a total of 26% since 1990, 
corresponding to approximately 2.1 million fewer deaths than what would have been 
expected.2 The decline in cancer-related deaths are attributed to the tremendous 
scientific advances made in understanding cancer at the molecular level. We now 
understand that cancer is a result of mutations, aberrant protein expression, or the 
ineffective turnover of proteins that drive tumorigenesis.3 These advances have allowed a 
transition from a “one size fits all” therapeutic approach, for example chemotherapy, to 
the era of rationally designed therapeutics that target specific signaling pathways that are 
defective in a specific cancer.4  
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 Targeted therapies allow healthcare providers to personalize therapeutic 
strategies based on the molecular cause of cancer revealed by gene sequencing and 
pathology of the tumor from the individual patient.5 Indeed, targeted therapies and 
personalized medicine have played a large role in the recent successes of fighting cancer.6 
However, cancer is a heterogeneous disease and developing targeted therapies that are 
effective for all patients remains a difficult challenge.7 Furthermore, cancer cells are 
constantly evolving which often results in resistance to targeted therapies in many 
patients.7 Mechanisms of resistance previously identified in clinical studies include 
mutation of the drug target that negates drug binding, reactivation by the signaling 
pathway via another mechanism, or activation of an alternative pathway.8, 9 Thus, new 
therapeutic approaches that account for the heterogeneous and elusive nature of cancer 
are urgently needed to make cancer therapies more effective. 
The immune system is adequately equipped to combat cancer due to the high 
degree of specificity and adaptability that can match the heterogeneity of cancer.10 
Furthermore, the immune system can protect against similar cancers from reappearing by 
developing immunological memory against cancer cells. The genetic and epigenetic 
alterations that take place in all cancer cells provide numerous mutated or aberrantly 
expressed proteins (termed neoantigens) that immune cells can use to differentiate a 
cancerous cell from normal cells, by a process referred to as immune surveillance.11 
Indeed, seminal studies by Schreiber and colleagues in 2001 were the first to demonstrate 
that CD8+ cytotoxic T cells protect against carcinogen-induced cancers in mice.12 Unless 
3 
 
 
otherwise noted, the term “T cell” will refer to CD8+ cytotoxic T cells for purposes of this 
thesis. 
Since these studies, efforts to invigorate the immune system by the development 
of vaccines and T cell activating cytokines were largely unsuccessful and little was known 
why these approaches were ineffective.13 However, recent developments have further 
elucidated the cellular and molecular mechanisms that orchestrate the complexities of T 
cell function.10 These discoveries have resulted in a greater understanding of how T cells 
modulate anti-tumor responses allowing for the design of novel therapeutic strategies to 
activate the immune response towards cancer.11 
T cell immunity includes multiple sequential steps involving clonal selection, 
activation, and proliferation by dendritic cells, trafficking, recognition, and elimination of 
foreign antigen displaying cells (Figure 1-1).14 A major breakthrough in cancer 
immunotherapy was the discovery that T cell activation and function is highly regulated 
by an intricate balance between activating and inhibitory signaling pathways, termed 
immune checkpoints (Figure 1-2).11 These checkpoints either inhibit or activate T cell 
activity at differences stages of the T cell life cycle. Under normal physiological conditions, 
the inhibitory checkpoints avoid uncontrolled immune responses, protect healthy cells 
from collateral damage during an immune response, and prevent autoimmunity.15  
James Allison and colleagues were the first to hypothesize that inhibiting negative 
immune checkpoints with therapeutics could enhance the anti-tumor activity of T cells.16 
Indeed, monoclonal antibodies (mABs) that target the first two inhibitory immune 
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checkpoints identified, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and 
programmed cell death protein 1 (PD-1)  demonstrated remarkable success in patients 
with advanced staged melanoma.17 Because these therapies target the immune system 
and not the cancer cell, these therapeutics could be effective in many different histologic 
cancers and cancers caused by different genetic lesions.10 To date, both CTLA-4 and PD-1 
 
Figure 1-1: Cancer-Immunity Interface 
The complex interactions of the immune system with cancer cells (gray). Tumor antigen 
(yellow stars) are taken up by dendritic cells and used to activated T cells in the lymph 
node. Activated T cells with TCR that recognize tumor antigen then migrate to the tumor 
microenvironment where they bind to antigen-MHC complexes and kill the cancer cells. 
Image adapted from Mellman et al, 2011.14 
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blocking agents have demonstrated durable responses in 11 different cancer types and 
their indications are continuously expanding.18 Theses success combined with the success 
of other immune activating therapies including anti-tumor vaccines, CAR T cells, oncolytic 
viruses, and bi-specific T cell engagers fusion proteins (BiTEs) were designated as 
 
Figure 1-2: Immune checkpoints that regulate T cell function 
Recently identified activating and inhibitory immune checkpoint interactions that regulate T cell 
activation and function. Image adapted from Pardoll 2012.11 
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“breakthrough of the year” by science in 2013 and are revolutionizing the way physicians 
treat many cancer patients.19-22 Indeed, immunotherapy is now considered the 5th pillar in 
cancer care alongside surgery, radiation, targeted therapy, and chemotherapy.23 
1.2 CTLA-4 is a validated target for cancer immunotherapy 
T cell activation is a highly regulated process to avoid over-stimulation of the 
immune response.24 Antigen presenting cells (APCs) process tumor-specific proteins that 
originate from aberrant expression and/or highly mutated proteins originating from 
tumor cells. APCs present small peptide segments of the tumor-specific protein bound to 
the major histocompatibility complex (MHC) on the surface of the cell to interact with the 
TCR on naïve T cells.25  If the TCR of a naïve T cells binds to the antigen-MHC complex, the 
first activation signal is sent via TCR signaling. A secondary co-stimulatory signal by CD28 
binding to either B7-1 or B7-2 (also known as CD80 and CD86, respectively) is also 
required for T cell activation.26 Sufficient levels of CD28: B7 stimulatory signaling causes 
the production of interleukin 2 (IL-2) resulting in T cell proliferation and cell survival 
(Figure 1-3A). Activated T cells migrate to the tumor microenvironment and eliminate 
cells that display the tumorigenic antigen bound to MHC molecules.24 
T cell activation is counterbalanced by the inhibitory co-receptor CTLA-4.27 The 
importance of CTLA-4 is demonstrated by the lethal T cell proliferative disorder found in 
CTLA-4 knockout mice.28 In naïve T cells, CTLA-4 is sequestered in intracellular vesicles. 
TCR: MHC signaling causes CTLA-4 to be translocated to the surface of the T cell.29 The 
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amount of CTLA-4 that is translocated is proportional to the strength of the TCR signal 
creating a graded inhibitory feedback loop of T cell activation (Figure 1-3).30, 31 CTLA-4 is a 
homolog of CD28 but binds to B7-1 and B7-2 with higher affinity (> 7 fold).32 Thus, the 
 
Figure 1-3: CTLA-4 inhibits T cell activation 
CTLA-4 mechanism of T cell activation. A) When TCR recognizes MHC-antigen complex 
T cells are primed for activation by the co-stimulatory signal CD28 binding to B7. B) After 
TCR signaling CTLA-4 is translocated to the cell membrane and outcompetes CD28 for 
binding to B7 preventing activation. C) Cell extrinsic mechanisms of inhibition by CTLA-4 
expression on Treg cells that can compete with CD28 for binding to B7. Image adapted 
from Buchbinder et al. 2016.31 
A) 
C) 
B) 
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proposed mechanism of CTLA-4 mediated T cell inhibition is by outcompeting CD28 for 
binding to B7-1 and B7-2 preventing the secondary co-stimulatory signal (Figure 3B).33 
However, more recent data suggest CTLA-4 may inhibit T cell activation by cell-extrinsic 
mechanisms.34 CLTA-4 is highly expressed on Treg cells and can bind to B7 ligands on the 
APC preventing CD28 co-stimulation (Figure 3C).35 Interestingly, Treg cells can also 
physically remove B7 ligands from APC cells by trans-endocytosis.36 While the precise 
mechanism(s) of CTLA-4 is currently debated in the literature, inhibition of CTLA-4 has 
been demonstrated to be a highly validated strategy to reverse the inhibition of T cell 
activation. 
Preclinical studies of CTLA-4 blocking antibodies achieved complete tumor 
rejection and long-lived immunity in mouse models with immunogenic tumors.16 These 
results translated into human clinical trials using an anti-CTLA-4 fully humanized antibody 
(ipilimumab, developed by Medarex and Bristol-Myers Squibb).37 Ipilimumab 
demonstrated a 3.5-month survival benefit for patients with advanced melanoma 
compared to a melanoma-specific protein vaccine (gp100).37 Strikingly, 20% of patients 
treated with ipilimumab demonstrated long-term durable responses.38 Notably, 
ipilimumab was the first therapy to significantly improve the survival of metastatic 
melanoma patients.39 Recent updates from this clinical trial indicate that a subset of these 
patients are cancer free 10 years post-treatment.40 Given these successes, ipilimumab 
was FDA approved in 2010 for patients with advanced melanoma.41 Ipilimumab has also 
resulted in tumor regression in phase I/II clinical trials in patients with renal cell 
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carcinoma, prostate cancer, urothelial carcinoma, and ovarian cancer.42-44 Many other 
clinical trials for ipilimumab and other anti-CTLA-4 antibodies are currently ongoing. 
1.3 The PD-1 signaling pathway is a validated target for cancer immunotherapy 
Shortly after the success of CTLA-4, another inhibitory checkpoint protein was 
identified termed programmed cell death 1 (PD-1).45, 46 PD-1 is expressed on activated T 
cells and inhibits T cell activity when bound to its ligands PD-L1 and PD-L2.47 PD-L2 is 
primarily expressed on antigen presenting cells whereas PD-L1 is expressed on many cell 
types including immune cells, epithelial cells, and endothelial cells.10 Thus, PD-L1 
mediated PD-1 signaling is thought to be a key regulator of immune homeostasis by 
controlling inflammation in the periphery.48, 49  
Upon antigen recognition, T cells produce inflammatory cytokines that initiate an 
immune response. Pro-inflammatory cytokines released from immune cells, namely 
interferon gamma (IFN-γ), result in PD-L1 expression in cells (Figure 1-4).50 When engaged 
to PD-L1, PD-1 recruits SHP phosphatases to its ITIM signaling motifs causing 
dephosphorylation of ZAP70 and PI3K which ultimately results in decreased cytokine 
production, cell cycle arrest and a decrease in the pro-survival factor Bcl-XL.51 The final 
result is the inactivation of the T cell and the survival of the target cell.52  Failure to 
counterbalance T cell activity can cause serious immune-related tissue damage that can 
be fatal to the host.53 Indeed, PD-1 or PD-L1 deficient mice develop lethal 
immunopathology following chronic infection with a lymphocytic choriomeningitis virus.54 
In addition to downregulating inflammation, PD-1 also plays a role in regulating 
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autoimmunity.55 The activation, proliferation, and differentiation of T cells that recognize 
healthy cell antigens (autoreactive T cells) are downregulated by PD-1 signaling. The 
diverse functions of how PD-1 regulates immune homeostasis remains a highly active area 
of research. 
Given these mechanistic insights, PD-1 has obvious implications in cancer 
therapy.56 Indeed, many different types of cancer cells have been shown to upregulate 
expression of PD-L1 by the activation of myc and other oncoproteins. 57, 58 The 
overexpression of PD-L1 on tumor cells is thought to be one of the major mechanisms by 
which cancer cells evolve to evade the immune response. Indeed, PD-L1 expression on 
 
Figure 1-4: Mechanism of PD-1 inhibition of effector T cell function. 
PD-1 is expressed after T cell activation and is inhibited by binding to its ligand PD-L1. PD-L1 
expression is induced by IFN-gamma release from T cells and by oncogenic activation. Image 
adapted from Buchbinder et al. 2016.31 
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cancer cells induced by INFγ and by oncogenic activation generally correlates with a poor 
prognosis compared to PD-L1- tumors in a variety of different cancer types.59-61 PD-1 and 
PD-L1 blocking mABs have been developed to remove the immune evasion mechanism of 
cancer cells and “release the brakes” from cancer-specific T cells.  
PD-1 and PD-L1 blocking mABs have been developed to remove the immune 
evasion mechanism of cancer cells and “release the brakes” from cancer-specific T cells. 
The first clinical trials of these agents in 2010 resulted in antitumor activity in patients 
with colorectal cancer, melanoma, and renal cell carcinoma with acceptable toxicity 
profiles.11 Since then the FDA has approved anti-PD-1/PD-L1 agents in a large variety of 
cancers including melanoma, non-small cell lung cancer, MSI-H/dMMR cancers, renal cell 
carcinoma, Hodgkin’s lymphoma, urothelial carcinoma, head and neck squamous cell 
carcinoma, Merkel-cell carcinoma, hepatocellular carcinoma, and gastric cancer within a 
4-year period (Figure 1-5). While the response rate is relatively low (20 – 30%), patients 
that respond to anti-PD-1 therapy have remarkable long-term durable responses.62 To 
date, there are 5 anti-PD-1/PD-L1 antibodies that are FDA approved in 11 different cancer 
indications that are continuously expanding (Figure 1-5). Taken together, the 
development of therapeutics that target the PD-1 pathway has been one of the most 
important advances in the history of cancer treatment.17  
1.4 Current immunotherapy clinical trial landscape 
One of the major questions that have resulted from both CTLA-4 and PD-1 
blocking therapy is why a 70 to 80%  of patients fail to respond.63 The heterogeneous 
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response to these agents has resulted in large efforts to develop biomarkers to predict 
clinical responses. Current biomarkers that are being used include PD-L1 expression on 
tumor and immune cells 64, mutational/neoantigen load 65, 66, and inflammatory gene 
signatures 67, 68. However, the complexity of the cancer-immunity response has made 
finding reliable markers that correlate with clinical responses challenging.69 In parallel, 
massive efforts have been placed on designing combination studies to try and improve 
the overall response rate and improve the quality of the response.68 Because the CTLA-4 
and PD-1 checkpoint pathways have different mechanisms of T cell regulation, 
combinations of the two checkpoint inhibitors are predicted to be synergistic and increase 
the response rate. This combination was tested in melanoma patients and resulted in 
 
Figure 1-5: Timeline of immune checkpoint targeting monoclonal antibodies 
Blue dot indicates first patient dosed. Red dot indicates first FDA approval for indication. 
Ipilimumab is a anti-CTLA-4 antibody. Nivolumab (BMS) and Pembrolizumab (Merck) are 
anit-PD-1 antibodies. Atelizumab (Genentech/Roche), Durvalumab 
(Medimmune/AstraZeneca) and Avelumab (Merck/Pfizer/Eli Lilly) are anti-PD-L1 antibodies. 
Figure adapted from Ribas et al. 2018 17 
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greater than 50% response rate which is approximately 2 times higher than either alone 
(Figure 1-6A).70 However, this combination also resulted in significantly higher incidents of 
high-grade toxicities (60%) than seen in either therapy alone.70 
With precedent for synergistic combinations, there are now considerable efforts 
to find additional combinations with checkpoint mABs that increase the response rate 
while limiting immune-related adverse events (irAEs).68 The primary rationale is to utilize 
 
Figure 1-6 Immune checkpoint inhibitor combinations in clinical trials. 
A) Representative survival curve of chemotherapy, targeted therapy, CTLA-4 and PD-1 
monotherapy and combination of CTLA-4 and PD-1 compared to a hypothetical survival curve of 
CTLA-4, PD-1 and some other therapy designated X. B) Diagram of combinations clinical trials 
combining different aspects of cancer therapies. C) Number of clinical trials ongoing for PD-1/PD-
L1 inhibitors. A) adapted from Emens et al 2017,62 B) adapted from Melero et al. 2015,71 C) 
adapted from Tang et al. 2018.72 
A) B) 
C) 
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chemotherapy, radiotherapy or targeted therapy that cause cancer cell death and the 
release of a diverse set of cancer antigens that can activate naïve T cells. Activated tumor-
specific T cells that recognize a diverse series of tumor antigens in the presence of 
immune activators may generate a higher response rate than seen in previously (Figure 1-
6A, red dashed line).62 Indeed, there are currently over 1,000 clinical trials involving anti-
PD-1/PD-L1 antibodies as monotherapy or in combination with numerous diverse 
therapies including chemotherapy, radiotherapy, virotherapy, targeted therapies, 
vaccines, and other immune modulators (Figure1-6 B-C).71, 72 Preliminary data from many 
of these trials are promising and the results will lead to a greater understanding of how to 
further optimize checkpoint immunotherapy.73 
1.5 Immune-related adverse events 
Therapies that activate the immune system can result in irAEs. The prevalence, 
severity, and management of various irAE’s with checkpoint inhibitors in many cancer 
types have been reviewed extensively.70, 74-82 In large clinical trials, approximately 70% of 
patients treated with anti-PD-1 antibodies as a single agent have documented treatment-
related AEs (of any grade), with 35% of patients needing immunosuppressants to control 
irAEs.70, 78 While most of these adverse events are low grade, high grade irAE’s occur in 
14% of patients with 7% of patients ultimately discontinue treatment.83-86 While every 
organ system can be affected by these therapies, the most common irAEs include 
dermatitis, hepatitis, endocrinopathies, and pneumonitis.87-93 Less frequent irAEs have 
been reported that affect the renal, cardiac, neurological, ocular and pancreatic 
systems.84, 86, 88, 89, 94-100  Permanent thyroid dysfunction, type 1 diabetes,  and deaths 
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resulting from cardiotoxicity and pneumonitis have also been reported.83, 92, 101-103 While 
there are now trials to lower the doses of these antibodies to limit the toxicities, higher 
toxicity rates are expected in combination with other therapies in attempt to increase the 
clinical efficacy rate.  
1.6 Rationale for small molecule inhibitors 
Therapeutic antibodies that selectively target immune checkpoints have been 
successful as single agents in numerous clinical trials. Although the current antibody-
based therapies can offer substantial benefits, there are inherent drawbacks to 
therapeutic antibodies that have implications when targeting immune modulating 
signaling pathways.104 First, PD-1 expressing effector T cells are found to be infiltrated 
within the solid tissue of PD-L1 expressing tumors. Deep tissue penetration of antibodies 
is problematic due to their large size (150 kDa) and may suggest why current therapeutics 
have sub-optimal efficacy.104, 105 Another inherent problem with antibodies is the 
presence of the Fc chain that may have off-target immune responses by macrophages and 
natural killer cells.106 Given that both PD-1 and PD-L1 are expressed on effector T cells, 
antibodies that bind to either protein may counterproductively deplete effector T cells via 
Fc mediated cytotoxicity.104 Indeed, clinical data suggests there is a correlation between 
anti-PD-1 antibodies and lower amounts of circulating effector T cells in patients.107  
Furthermore, currently used antibodies have half-lives on the order of 3 to 4 
weeks.107 In fact, the current antibodies bind PD-1 with such high affinity, they stay 
engaged to the receptor for more than 2 months after circulating antibodies have been 
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cleared from the system.87, 107 Long-term inhibition of the CTLA-4 and PD-1 signaling 
pathways can potentially result in off-target T-cell activation to induce unexpected 
autoimmunity.74 Indeed, clinical data suggests that long term immune checkpoint 
blockade is a significant contributor to irAEs.87, 107 Hence, other blocking agents with 
improved toxicity profiles may offer a more tolerable combinatorial therapy for cancer 
patients. 
These disadvantages of mABs have been partially corroborated by a group that 
engineered PD-1 (15 kDa) with a series of mutations that resulted in a 30,000 fold 
increase in binding to PD-L1.104 When compared to an anti-PD-1 antibody using in vivo 
tumor models, the PD-1 mutant demonstrated superior tissue penetration, maintained 
normal peripheral effector T cell counts and had superior tumor suppression efficacy. 
These findings suggest therapeutic strategies to inhibit PD-L1 / PD-1 signaling in the 
tumor microenvironment can be further optimized by using low molecular weight 
inhibitors of PD-L1 compared to the large antibodies used currently.  
An alternative therapeutic approach is to use small molecules to block the PD-1 / 
PD-L1 or CTLA-4 / B7 interactions. Small molecule inhibitors of these pathways have the 
potential to address the problems associated antibody-based therapeutics. A small 
molecule inhibitor could be more cost-effective, have enhanced tumor penetration, and 
will not deplete T cells via Fc mediated toxicity mechanisms. Because the pharmaceutical 
and pharmacokinetic profile of a small molecule can be more easily modulated during the 
drug discovery process, they offer the potential for designing inhibitors with shorter half-
lives and enhanced tissue penetration and distribution. Small molecule inhibitors with 
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dynamic pharmacokinetic profiles will allow for patient-dependent dosing strategies to 
achieve the maximum efficacy while minimizing irAEs, thereby broadening the 
therapeutic window. If significant irAEs are detected, a small molecule inhibitor would be 
rapidly cleared from the body such that treatment could be simply discontinued rather 
than supplementing with high doses of steroids with their own set of toxicities into the 
patients. As clinicians expect greater adverse effects from immunotherapy combinations 
moving forward, small molecule inhibitors can potentially lower significant immune-
related toxicities to allow for more successful combinatorial immunotherapies.  
In addition to toxicity, the expense of using antibodies as single agents and in 
combination is a significant concern. Given that the production of antibodies is a complex 
process, they generally have a higher cost of production and are more expensive 
compared to small molecule therapeutics.108 Indeed, pembrolizumab (Merk’s anti-PD-1 
antibody) costs $150,000 per patient per year and a combination of pembrolizumab with 
Ipilimumab (BMS’s anti-CTLA-4 antibody) costs $254,000 per patient per year.109 
Expensive therapeutics place a large burden on both patients and health care systems 
throughout the world. In fact, the National Institute for Health and Care Excellence (NICE) 
that advises English and Welsh sectors of the U.K.'s National Health service has recently 
rejected Nivolumab (BMS’s anti-PD-1 antibody) for patients with head and neck cancer 
because Nivolumab’s price is too high.110 Hence, the development of a PD-L1 small 
molecule inhibitor with a lower cost of production could greatly reduce the expense of 
this therapy making the promising advances of immunotherapy available to patients in 
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health care markets throughout the world and to patients who cannot afford the current 
therapeutics.  
Despite these potential advantages, the discovery of small molecule inhibitors has 
lagged behind mABs. This is likely because CTLA-4, PD-1 and PD-L1 proteins are predicted 
to be highly challenging drug targets for small molecules.111 The protein-ligand interaction  
interfaces are large (> 1,200 A2) and lack deep hydrophobic pockets traditionally found in 
more druggable proteins.112 Consistent with this notion, no small molecule inhibitors have 
entered clinical trials for CTLA-4 or PD-1. A peptidomimetic inhibitor of PD-L1 from Curis 
Inc. has entered clinical trials, but the series of these molecules lack direct binding data to 
PD-L1.113, 114  We (and others)115 have profiled these compounds and found no direct 
binding to either PD-1 or PD-L1, suggesting an alternative mechanism for these 
compounds. Thus, there is a need for the development of novel small molecule inhibitors 
of CTLA-4, PD-1, and PD-L1. 
1.7 Fragment-based drug discovery 
Protein-protein interactions that consist of flat and large surface areas can be 
extremely difficult to target by small molecules. Given that many validated cancer targets 
are also some of the most challenging for small molecules, many have explored novel 
drug discovery methods to discover small molecules that bind to challenging targets. 
Fragment-based drug discovery (FBDD) methods in combination with structure-based 
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design was first shown by Fesik and co-workers at Abbott labs to be a highly effective way 
to target difficult targets.116 Over the past 20 years, FBDD has been used to successfully 
generate high-affinity ligands to targets that were previously thought to be 
“undruggable”. Examples include Venetoclax and Vemurafenib that are FDA approved to 
target Bcl-2 and B-Raf(V600E), respectively.117, 118 There are many more molecules that 
originated from fragments that are currently in optimization development and clinical 
trials.119  
 
Figure 1-7: Overview of fragment-based drug discovery 
Overview of FBDD. A) Hypothetical hit compound identified from an HTS screen. Ligand binds with 
moderate affinity but fails to occupy all sub-pockets at the binding site. B) Hypothetical fragment 
hit identified from a fragment screen. Fragments binds with lower affinity but more efficiently 
occupy sub-pockets at the binding site. C) Optimization of fragments is an iterative process 
involving many rounds of structure determination, modeling and rational synthesis and 
determination of binding affinities. Images adopted from Scott et al 2012. 122 
A) B) 
C) 
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Fragment-based approaches consist of screening low molecular weight 
“fragments” (less than 300 Dalton) for direct binding to the protein. Fragments can cover 
more chemical space with much smaller libraries compared to traditional high throughput 
screening (HTS) methods that use compounds with higher molecular weights.120 The 
number of hits per number of compounds screened (hit rate) from an HTS screen can be 
low depending on the druggability of the target and hits are predicted to bind with lower 
micromolar affinity. Given the complexity of the molecules, they often make numerous 
suboptimal interactions in the binding pocket requiring extensive SAR to optimize 
compound binding (Figure 1-7A).121 Conversely, fragments make fewer interactions that 
are often higher quality and result in high ligand efficiency (Figure 1-7B).122 Thus, 
fragment screens often identify chemotypes that bind to proteins containing shallow 
binding pockets that would otherwise be missed in a HTS screen.120 However the binding 
affinity of fragments are typically in the high micromolar to low millimolar affinity due to 
their small size and need extensive optimization to discover drug-like molecules. 
With structural information of fragments bound protein, fragments can be further 
optimized to bind to the target with high-affinity using multiple structure-based design 
strategies. If two fragments were identified in the screen to bind in close proximity, 
fragments can be covalently linked to rapidly increase the binding affinity. Indeed, the 
predicted binding affinity of a linked compound is equal to the product of the Kd of the 
first ligand and the Kd of the second ligand multiplied by a linking constant (Kdlinked = 
Kd1st * Kd2nd * L).116 If all fragments identified in the screen bind to the same location on 
the protein, typically a second fragment screen is necessary to find fragments that bind to 
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an adjacent pocket that may be induced by the first fragment binding. To conduct a 
second site screen, the first fragment is often optimized by fragment growing or fragment 
merging approaches to improve the binding affinity of the first ligand. The library is then 
screened again at saturating concentration of the first-site ligand. Lead compounds are 
iteratively optimized to improve binding affinity using structural information obtained by 
X-ray crystallography or NMR and molecular modeling experiments to generate high-
affinity molecules (Figure 1-7C).121 
Fragment-based methods require a reliable assay to monitor the binding of 
compounds with weak binding affinities (< 5 mM). Compared to other biophysical 
methods,  protein observed NMR is arguably the most robust method for conducting 
fragment-based screens.123 This method utilizes uniformly 15N (or 13C) labeled protein and 
obtaining 1H/15N (or 13C) HSQC spectra of the protein of interest in the presence and 
absence of fragment mixtures (Figure 1-8). Peaks observed in HSQC spectra correspond to 
the amide backbone NH groups on the protein. Each peak in the HSQC spectrum 
corresponds to a specific amino acid in the protein. Ligand binding to the protein causes 
chemical shift changes in peaks at the protein binding site. The chemical shift changes can 
be easily observed by overlays of an HSQC with and without ligands (Figure 1-8C). 
Advantages of screening by protein-observed NMR methods include (1) monitoring of the 
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direct interaction with the protein that results in very few false positives; (2) ability to 
measure the binding affinity without the need for a secondary assay; (3) ability to 
distinguish between fragments that bind to different sites on the protein by monitoring 
chemical shift patterns; and (4) ability to identify binding sites on the protein if the 
backbone resonance assignments are known.123, 124 Additionally, recent advances in NMR 
technologies have allowed for rapid acquisition of 1H/15N HMQC spectra and automated 
sample changers allowing for fragment screening by NMR to be a medium throughput 
assay.125  
If the protein structure of a target is known prior to the screen, druggability 
analysis by various algorithms can be used to identify “hotspots” for small molecules and 
 
Figure 1-8: 2D NMR methods for fragment screening. 
Overview of fragment screening by 2D NMR. Protein of interest is 15N labeled by expression in 15N 
rich media. Purified 15N labeled protein is mixed with fragment mixtures. A HSQC or similar 
experiment is run on an NMR spectrometer to generate a HSQC Spectrum. Overlays of spectra with 
and without fragment reveals fragment interacting with the protein by observation of chemical shift 
changes in peaks. Each peak corresponds to an amino acid on the protein and can be used to map 
the binding site of the fragment to the protein structure if the resonance assignments are known. 
15 15 15
Black = apo
Red = with fragment
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predict the ability to find hits from a screen.126, 127 However, these computational 
methods often assume a rigid protein and fail to account for protein dynamics or ligand-
induced binding. Thus, experimental assessments of a target’s druggability are often 
warranted. Previous studies have demonstrated that fragment screening by NMR has a 
high correlation with the ability to identify high-affinity protein ligands.128 Indeed, 
experimental evidence suggests targets with hit rates > 0.1% from a fragment screen are 
likely druggable targets. Thus, fragment screens can be used to experimentally assess 
protein druggability and aid in important decisions about the prioritization of targets in a 
drug discovery program. 
1.8 Scope of this thesis 
In the following chapters, I describe my efforts to develop novel small molecule 
inhibitors of the immune checkpoints CTLA-4, PD-1 and PD-L1 using fragment-based 
methods and structure-based design. In chapter 2, I describe the design of a monomeric 
CTLA-4 construct and the results of a fragment-based screen of monomeric CTLA-4. In 
chapter 3, I describe results of a fragment-based screen of PD-1, results from an analog 
screen and preliminary hit validation. In chapter 4, I describe efforts to optimize a PD-L1 
construct to conduct a fragment screen, the results from the fragment screen, hit 
validation and optimization of fragment hits by structure-based design.  In chapter 5, I 
describe efforts to validate literature reported PD-1 and PD-L1 inhibitors and efforts to 
merge fragment hits with other inhibitors. In chapter 6, I summarize all results and discuss 
the future direction for the development of small molecule inhibitors of these highly 
validated but challenging targets.
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Chapter 2 
Fragment Screen of Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) 
2.1 Introduction 
2.1.1 CTLA-4 is a negative regulator of T cell activation 
After T cells are primed for activation by TCR signaling, CTLA-4 is translocated to 
the cell surface and outcompetes CD28 for binding to its ligands B7-1/B7-2 (also called 
CD80/86).33 B7 ligands occupied by CTLA-4 results in the removal of the secondary 
activation signal from CD28. Without the secondary activation signal, the naïve T cell 
becomes anergic and undergoes apoptosis (Figure 2-1). CTLA-4 inhibitors restore the 
ability of CD28 to bind to B7-1/2 resulting in increased levels of T cell proliferation, 
differentiation, and T cell survival (Figure 2-1).129  Inhibition of CTLA-4 by mABs have been 
highly effective in the clinical setting making CTLA-4 a validated anti-cancer target.130 
While small molecule inhibitors are predicted to have many pharmaceutical advantages 
over mABs, there are no reported small molecules that bind to CTLA-4 reported in the 
literature.  
2.1.2 CTLA-4 Structure and function 
CTLA-4 is a highly conserved protein that shares 30% sequence identity to CD28 
(Figure 2-2D).131 The 3D structure of monomeric CTLA-4 and dimeric CTLA-4 have been 
determined by NMR spectroscopy and X-ray crystallography, respectively (Figure 2A-
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B).132-134 Based on its tertiary structure, CTLA-4 belongs to the immunoglobulin 
superfamily (IgSF) protein class, sharing key structural characteristics with 
immunoglobulin variable domain folds (IgV). Two b-sheets of the V-fold make the ABED 
and A’GFCC’ strands in the extracellular portion of CTLA-4. The two sheets are connected 
by a canonical Ig-disulfide (Cys 23 – Cys 94) between B and F strands in IgV folds and an 
additional internal disulfide bond (Cys 49 – Cys 68) between C and D strands.  
CTLA-4 is thought to function as a homodimer at the cell surface. In addition to an 
intramolecular disulfide bond at C122, a series of highly conserved hydrophobic residues 
(YVIDPE) stabilize the dimer conformation (Figure 2-2C).132 Given the high homology with 
CD28, a different conserved sequence is observed at this position for CD28 (HVKQKH) is 
thought to prevent CTLA-4 and CD28 forming heterodimers (Figure 2-2D).133 CTLA-4 is 
 
Figure 2-1: Inhibition of CTLA-4 restores T cell activation 
T cell activation requires signaling from both TCR and CD28. CTLA-4 is expressed after TCR 
signaling and outcompetes CD28 binding to CD80/86 (also referred to as B7-1/B7-2). Therapies 
that target CTLA-4 restore the CD28 / B7 interaction resulting in T cell activation. Image adapted 
from Vasaturo et al. 2013. 129 
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glycosylated at two highly conserved N-linked glycosylation sites (Asn 78 and Asn 110) 
that are distant from the B7 binding site (Figure 2B, sticks). Glycosylation is thought to 
play a role in CTLA-4 dimer formation, as CTLA-4 mutants of both N78 and N110 to 
alanine fail to dimerize on cells.135 However, a monomeric triple mutant of CTLA-4 (N78A, 
N110A, C122A) does not prevent CTLA-4 from localizing to the immunological synapse 
and inhibiting T cell function.135 Thus, the exact role that glycosylation and dimerization 
play in CTLA-4 function remains unclear. 
 
Figure 2-2: CTLA-4 primary and tertiary structure 
A) 3D Structure by NMR with labeled ß-strands. B) X-ray structure of dimeric CLTA-4. Disulfide bonds 
are highlighted by sticks. Glycosylation residues are highlighted by sticks and labels. C) Highlight of 
the highly conserved and hydrophobic CTLA-4 homodimer interface D) Multiple sequence alignment 
of CLTA-4 and CD28 from human, mouse, and rat species. Highly conversed resides for both proteins 
are highlighted red, conserved residues for only CTLA-4 are highlighted in blue and green for CD28. 
Residues that are conserved by similar chemical properties are highlighted in yellow. Figure adapted 
from Schwartz et al. 2001. 133 
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CTLA-4 and B7 proteins have been co-crystallized as alternating networks of 
bivalent CTLA-4 homodimers binding to  B7 ligands (Figure 2-3A).133, 134 The periodic 
assembly of dimeric molecules is characterized by a 105 Å repeat that extends throughout 
the crystal packing network. The 103 Å distance from B7 to CTLA-4 is consistent with the 
maximum dimensions of receptor/ligand pairs that co-localize to the central region of the 
 
Figure 2-3 CTLA-4 bivalent binding modes to B7 proteins 
A) X-ray structure of CLTA-4 bound to B7-1 results in a repeated array of CTLA-4 and B7-1 
homodimers thought to be biologically relevant. B) Model to explain why CTLA-4 has higher binding 
affinity to B7 proteins compared to CD28 by bivalent binding modes.  Image adapted from Walker et 
al. 2011.34 
T-cell membrane
APC membrane
103 Å
105 Å
B7-1
CTLA-4
A) 
B) 
B7-1B7-2B7-1B7-2
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immunological synapse, including the MHC / TCR complex.133 This zipper-like 
oligomerization could rationalize the formation of highly stable inhibitory complexes at 
the T cell / APC interface. Indeed, bivalent binding modes can offer an explanation of 
differences in the measured binding affinities of the B7 proteins and CTLA-4 or CD28 
(Figure 2-3B).32 The B7-1 / CTLA-4 is the highest affinity interaction due to bivalent 
binding mode of both CTLA-4 and B7-1. While CTLA-4 the binds B7-2 bivalently, B7-2 
cannot homodimerize and inability to form the zipper-like oligomerization rationalizes a ~ 
10-fold decrease in binding affinity. CD28 forms a homodimer but does not bind to either 
B7 protein bivalently resulting in weaker binding. These structures and kinetic studies 
support the hypothesis that CTLA-4 outcompetes CD28 for binding to the B7 proteins and 
preventing co-stimulatory signals and T cell activation. 
2.1.3 CTLA-4 binding hotspot 
The CTLA-4 binding interactions to B7-1 and B7-2 are highly similar.133, 134 The 
binding interface is formed by a shallow surface of the G, F, C, C’ and C’’ strands of B7. The 
total buried surface area is ~ 1,200 Å consists of 13 CTLA-4 residues and 13 residues of B7-
1. In total, there are 85 interatomic interactions consisting of 5 hydrogen bonds and many 
hydrophobic interactions. CTLA-4 makes significant contacts to this surface via the FG 
loop (also referred to as the CDR3 loop) containing the highly conserved MYPPPK 
sequence found in both CTLA-4 and CD28 proteins. These interactions exhibit a high 
degree of shape complementarity as neither protein undergoes significant conformational 
changes when bound compared to unliganded structures.136   
29 
 
 
In addition to CTLA-4 and B7 crystal structures, a structure of ipilimumab has also 
been determined.137 Ipilimumab and B7 proteins all bind to the highly conserved MYPPPK 
segment of CTLA-4 (Figure 2-4A-B). This overlap in suggests this region of the protein 
could be a hot spot for small molecule binding to displace B7 proteins (Figure 2-4C-D). 
Careful analysis of the MYPPPK surface reveals a shallow hydrophobic region of the 
 
Figure 2-4: CTLA-4 hotspot 
A) Overlay of co-crystal structures of B7-1 (purple) bound to PD-1 (gray) and ipilimumab (teal) 
bound to PD-1. B) surface of CTLA-4 that interacts with B7-1 (purple) and ipilimumab (teal) and the 
shared residues (blue). C) electrostatic potential of CTLA-4 with residues involved in the interaction 
with B7-1. D) CTLA-4 residues in green sticks that interact B7-1 suggesting potential binding sites for 
small molecules. 
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protein where fragments could potentially bind (Figure 4C-D). It is also possible that 
fragments could bind to an inducible binding pocket on CTLA-4 not seen in previous 
structures and thus warrants a fragment screening effort to assess the druggability of 
CTLA-4 by small molecules. 
2.2 Results 
2.2.1 Expression and purification of monomeric CTLA-4 
Large amounts of recombinant 15N-labeled protein are necessary to conduct a 
fragment-based screen. CTLA-4 (residues 2 – 126) was cloned into a pET28b E. coli 
expression vector to express CLTA-4 with a thrombin cleavable 6His tag at the N-terminus. 
6his-CTLA-4 was expressed as inclusion bodies. Insoluble inclusion bodies were first 
purified by a series of Triton X-100 and salt washing steps using centrifugation to pellet 
the inclusion bodies between wash steps. 6His-CTLA-4 inclusion bodies were solubilized in 
6M guanidine HCl and refolded dropwise into CTLA-4 refolding buffer. 6His-CTLA-4 was 
further purified and concentrated by loading to a nickel column. Eluted protein was 
dialyzed to remove imidazole and treated with thrombin to remove the 6His tag. CTLA-4 
was separated from the 6His tag and thrombin by size exclusion chromatography (Figure 
2-5A).  
Previous X-ray studies have indicated CTLA-4 forms a disulfide-linked 
homodimer.133 Indeed, the initial CTLA-4 construct (2 – 126) containing cystine 122 eluted 
mostly as a dimer from size exclusion chromatography (Figure 2-6A, gray line). 1H-15N 
HMQC spectra of both dimer and monomer peaks from size exclusion have similar peak 
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dispersion in HMQC spectra with dimer peaks having slightly lower peak intensity 
compared to the monomer peaks (Figure 2-6B). Peak dispersion is expected to be similar 
due to the dimer formation being at the flexible C-terminal tail of the protein. A weaker 
signal for the dimer peak is also expected due to the higher molecular weight and slower 
tumbling rate of a CTLA-4 dimer.  
X-ray structures of CTLA-4 bound to its ligands demonstrate that the binding site is 
distant to the dimerization site. Thus, screening a CTLA-4 monomer is preferred due to 
the enhanced signal and uniformity of the NMR sample. To prevent CTLA-4 dimer 
 
Figure 2-5 Purification of CTLA-4 
A) SDS PAGE gel of the CTLA-4 purification process. Lane 1: marker Lane 2: cell lysate prior to 
CTLA-4 induction by IPTG. Lane 3: CTLA-4 expression induced by IPTG indicated by band at 16.5 
kDa. Lane 4: Washed inclusion bodies (IB). Lane 5: Nickel affinity purification (IMAC) of refolded 
6His-CTLA-4. Lane 6: CTLA-4 with 6his tag removed by thrombin protease. Lane 7: Final 
purification step of size exclusion chromatography. B) Protein yields per liter of cell culture for 
each step of the purification process. C) HSQC of 15N labeled CTLA-4 indicates a well folded 
protein suitable for fragment screening.  
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formation, two constructs were designed to remove the C122 disulfide using site-directed 
mutagenesis. The first construct mutated C122 to serine and the second truncated the 
amino acid sequence to 2 – 121 by introducing a stop codon at 122. Neither mutant 
affected expression, refolding, and purification. However, both mutants eluted as a 
monomer on size exclusion as designed (Figure 2-6A). CTLA-4 C122S was selected for 
 
Figure 2-6: CTLA-4 mutants to produce monomeric CTLA-4 
A) Size exclusion elution profiles of wildtype CTLA-4 (gray), CTLA-4 C122S (orange), CTLA-4 stop121 
(blue). Wildtype with C122 forms a mixture of a dimer a monomer in solution. Mutants designed to 
prevent protein dimerization elute as monomers. B) HSQC of dimer and monomer peaks show 
similar peak dispersions with the dimer having slightly weaker signal intensity consistent with a 
larger protein. 
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fragment screening over truncated CTLA-4 (2 – 122) due to a slightly higher yield in the 
purification process. Purification of CTLA-4 C122S resulted in highly pure protein with 
yields of 4.6 mg/L of 15N M9 cell culture and high-quality HMQC spectra (Figure 5).  
2.2.2 Fragment Screen of CTLA-4 
NMR screening conditions were optimized by monitoring peak intensity in 1H-15N 
SOFAST HMQC spectra and adjusting the pH, salt concentrations, and protein 
concentrations. Optimal conditions were found to be 0.27 mg/mL protein (20 µM) in 
buffer containing 25 mM Sodium Phosphate, 100 mM NaCl, 1 mM DTT. Our 13,824 
membered fragment library was screened by recording 1H-15N SOFAST HMQC spectra of 
15N labeled CTLA-4 C122S in the presence of mixtures of 12 fragments at 800 µM 
concentration each. A mixture sample was labeled as a “hit” if chemical shift changes 
were observed in fragment mixture samples relative to a sample containing only DMSO 
(Figure 2-7). From the mixture screen, 25 mixtures were identified as hits. These mixtures 
were deconvoluted by testing all 300 fragments as singletons at 800 µM concentration. 
Surprisingly, none of the 300 fragments selected for deconvolution had detectable 
binding to CTLA-4. This phenomenon is common when selecting mixtures with weak 
chemical shifts for deconvolution. High concentrations of fragments mixtures (12 x 800 
µM, 9.6 mM concentration of organic compounds) can cause slight changes in the sample 
pH or cause minor destabilization of the protein that is not present when testing 
compounds as singletons. 
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2.3 Conclusions and Discussion 
Fragment screening is known to be a reliable predictor of the ability to develop 
small molecules that bind to a protein with high affinity. Despite screening our entire 
library, we were unable to discover any fragments that bind to CTLA-4. These results 
strongly suggest that CTLA-4 is undruggable by small molecules. We considered re-
screening the library against the dimeric form of CTLA-4 with aspirations to find hits that 
bind to the CTLA-4 dimer, presumably at the hydrophobic interface between the two 
monomers. However, CTLA-4 binds to its ligands at the FG loop which is distant from the 
dimer interface. Identification of fragments that bind to dimeric CTLA-4 would need to 
inhibit binding to B7-1 and B7-2 via an allosteric effect. Given the rigidity of the IgV fold 
 
Figure 2-7 CTLA-4 chemical shifts seen in a “hit” of a mixture of 12 fragments. Chemical shift 
changes are highlighted by blue arrows. 
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containing two internal disulfide bonds, it is unlikely that fragment binding to a CTLA-4 
dimer would induce large conformational changes to disrupt binding to its ligands.  For 
these reasons, we decided to deem CTLA-4 undruggable by small molecules and shift 
fragment screening efforts to other immune checkpoint proteins.  
2.4 Methods 
Cloning  
The extracellular domain of human CTLA-4 (residues 2 - 126) was cloned into the 
pET28b vector using NdeI and XhoI to contain a thrombin cleavable N-terminal 6-His tag 
and transformed into E. coli BL21 (DE3) cells. C122S and C122stop mutations were made 
by site-directed mutagenesis. Primers were designed using PrimerX 
(bioinformatics.org/primerx). PCR reactions contained 10 ng of template DNA, 10 µM 
forward primer, 10 µM reverse primer, and 1X Phusion High-fidelity Master Mix (NEB). 
Methylated DNA was removed by treatment with 1 µL of DPN1 for 1 hour at 37 ºC. The 
digested PCR product was transformed to competent E. coli DH5a by heat shock (45 
seconds at 42 ºC) and plated on Kanamycin treated LB-agar plates overnight at 37 °C. 
Isolated colonies were picked and grown overnight in 10 mL LB cultures. Plasmid DNA was 
extracted using a miniprep kit (Qiagen) and sequenced using a primer for the T7 promoter 
(Genhunter). 
Protein Expression and Purification 
Uniformly 15N labeled CTLA-4 was expressed as inclusion bodies in M9 minimal 
media containing 15N ammonium chloride. Protein production was induced with 1 mM 
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IPTG at OD600 at 0.8 and harvested 5 hours later. The cell pellet was frozen and 
resuspended in lysis buffer (50 mM Tris-HCl pH = 8.5, 150 mM NaCl, 20 mM DTT, 2 mM 
EDTA and 1 mM PMSF) prior to lysis by homogenization (APV-2000, APV). Inclusion bodies 
were collected by centrifugation and washed twice with the lysis buffer containing 2% 
Triton. Inclusion bodies were additionally washed with lysis buffer containing 1% Triton, 
0.5% Triton, and 1.5 M NaCl wash steps. Purified inclusion bodies were solubilized in 50 
mM Tris-HCl pH = 8.5, 250 mM, 6M Guanidine HCl for 4 hours at room temperature. The 
solubilized inclusion bodies were filtered through a 0.45 µm filter and refolded dropwise 
into the CTLA-4 refolding buffer (50 mM Tris-HCl pH = 8.5, 240 mM NaCl, 10 mM KCl, 2 
mM CaCl2, 2 mM MgCl2, 0.5% Triton X-100, 0.5 mM PMSF, 0.2 M arginine, 1M urea, 1 
mM reduced glutathione and 0.1 mM oxidized glutathione). After 48 hours the refolding 
buffer containing CTLA-4 was filtered and loaded to a ProBond nickel column (Thermo) 
using the refolding buffer as Buffer A and the refolding buffer + 500 mM imidazole as 
buffer B. Eluted CTLA-4 was dialyzed against 50 mM Tris-HCl pH = 8.5, 150 mM NaCl, 2 
mM DTT to remove imidazole. After dialysis, the N-terminal 6-His tag was removed with 
thrombin (10 units of thrombin per mg of CTLA-4). Monomeric CTLA-4 was collected from 
size exclusion chromatography (Superdex75 26/60) pre-equilibrated with NMR buffer (50 
mM Sodium Phosphate pH = 7, 25 mM NaCl). 
Fragment Screening 
 NMR screening was performed at 30 °C using a Bruker Avance III 600 MHz 
spectrometer equipped with a 5 mm single-axis z-gradient cryoprobe and Bruker 
SampleJet sample changer. Screening samples (500 µL) screened contained 20 µM of 15N 
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CTLA-4 C122S, 12 fragments at 800 µM each, and 5% DMSO-d6. 1H,15N SOFAST-HMQC 
spectra were obtained using 26 scans and analyzed using Topspin (Bruker BioSpin). 
Deconvolution of hit mixtures was performed as a single fragment at 800 µM 
concentration. CTLA-4 proteins were able to be recycled by filtering and loading to a 
buffer exchange column. 
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Chapter 3 
Fragment Screen of Programmed Cell Death-1 (PD-1) 
3.1 Introduction 
3.1.1 PD-1 inhibits activated T cell function  
 PD-1 is expressed on all activated T cells and acts as an inhibitory brake to tamper 
T cell immune responses as an immune tolerance mechanism.11 PD-1 inhibits T cell 
function when bound to either of its binding partners, PD-L1 or PD-L2. Cancer cells have 
exploited PD-1 tolerance signaling by overexpressing PD-L1. Expression of PD-L1 on 
cancer cells is thought to be one of the major mechanisms of immune evasion to promote 
cancer cell survival and growth.138 Inhibitors of PD-1 reactivate T cells and prevent the 
 
Figure 3-1: Targeting PD-1 pathway to reactive T cell activity against cancer cells. 
PD-1 binding to its ligand PD-L1/2 inactivates T cells that recognize cancer cells. PD-L1 is overexpressed 
on cancer cells as an immune evasion mechanism. Inhibitors of PD-1 prevent T cells from being 
inactivated by cancer cell expression of PD-L1. Image adapted by Vasaturo et al. 2013. 129 
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immune evasion mechanism of cancer cells. (Figure 3-1). Indeed, mAbs antibodies that 
target PD-1 have been remarkably successful in patients in a variety of cancer types.  
 Given the potential pharmaceutical advantages of small molecules inhibitors, two 
examples of small molecules that target PD-1 have been reported in the literature.139 
Molecules containing a sulfonamide moiety were reported first by a group at Harvard in 
2011, however, no follow-up to these molecules have been reported (Figure 3.2).140 
Amino and dimethyl carbamate-substituted resorcinol compounds have also been 
reported by a group in China in 2016 (Figure 3-2).141 All of these molecules are active in 
PD-1 / PD-L1 FRET assays with percent inhibition values that range from 10% to 42%. 1D 
NMR experiments suggest these molecules bind to PD-1, however, no binding affinities or 
structural information of the molecules bound to PD-1 have been reported. These results 
 
Figure 3-2: Previously identified PD-1 inhibitors.  
Inhibitory percentage reported from TR-FRET assay developed by Cisbio China. Image adapted from 
An Liu et al. 2016. 141 
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could serve as potential starting points for further optimization and suggest that PD-1 
could be druggable by small molecules.  
3.1.2 PD-1 Structure and function 
 PD-1 is a type I membrane protein that consists of 288 amino acids. The C-
terminus in the cytosol is highly conserved and consists of an ITIM signaling domain that is 
responsible for inhibition of TCR signaling. When engaged by ligand, PD-1 is 
phosphorylated at two tyrosine residues within the ITIM domain that recruits the tyrosine 
phosphatases (PTPs) SHP1 and SHP2.142 SHPs dephosphorylate multiple different kinases 
and antagonize TCR and CD28 signaling through the ERK and AKT signaling pathways. 
These inhibitory signals result in decreased T cell proliferation, cytokine production and 
survival of T cells.142  
 PD-1 has one extracellular domain (21 - 170) that belongs to the IgV family of 
proteins and is moderately conserved with mouse PD-1 (Figure 3-3). The 3D structure of 
human PD-1 has been determined by NMR spectroscopy and X-ray crystallography.112, 143 
Two B-sheets of PD-1 adopt a ß-sandwich fold stabilized by the conical IgV disulfide bond 
(Cys54 – Cys123). PD-1 has four predicted N-linked glycosylation sites (N49, N58, N75, and 
N116). However, glycosylation at these sites are not close the PD-L1 binding site of PD-1 
and do not play a role in binding of anti-PD-1 mABs or PD-L1.144  
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3.1.3 PD-1 hotspot for small molecules 
 PD-1 binds to both ligands with moderate affinity (8 µM for PD-L1 and 2 µM for 
PD-L2).143 The complex structure of PD-1 bound to PD-L1 was recently determined.112 PD-
1 binds to PD-L1 with 1:1 stichometry and neither protein is known to dimerize causing 
repeated oligomers as seen in CTLA-4. The total surface area of the interaction is 1970 Å2 
comprising of C’CFG strands of PD-1. The interface is mostly flat and consists of both 
 
Figure 3-3: Structure of the extracellular portion of PD-1. 
Ribbon structure of PD-1 with labeled strands. Disulfide bond is shown by sticks. Glycosylation sites 
are shown by sticks and labeled. Multiple sequence alignment of human and mouse PD-1. Identical 
residues are highlighted in red. Glycosylation sites are labeled by triangles, cysteines in disulfide 
bonds are labeled by circles and the free cysteine residue mutated to serine is labeled by a star. 
Image adapted by Zak et al. 2015. 112 
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hydrophobic and polar interactions. The hydrophobic residues of PD-1 (V64, I126, L128, 
A132, and L134) make key contacts to PD-L1 (Figure3-4, yellow sticks). The hydrophobic 
core is surrounded by a network of polar interactions including 18 hydrogen bonds (Figure 
3-4). Notably, PD-L1 binding induces a conformational change of the C C’ loop in PD-1 
(Figure 3-5, orange strand). This rearrangement results in the formation of 4 additional 
hydrogen bonds between residues of PD-1Q75 to PD-L1D26 and PD-1T76 to the backbone 
 
Figure 3-4: PD-1 / PD-L1 binding interaction 
Highlighted contacts of the PD-1 (blue) interaction with PD-L1 (green). Hydrophobic residues shown 
as yellow sticks. Hydrogen bonds shows as dotted lines. Image adapted from Zak et al 2015.112 
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carbonyl to PD-L1Y123(Figure 3-5). E136 and Y68 of PD1 also undergo conformational 
changes that result in Pi-Pi stacking of PD-L1Y56 to Y68PD-1. This results in the formation of a 
pocket at the center of the PD-1 interaction (Figure 3-5). The authors speculated that this 
pocket could be suitable for the binding of small molecule tyrosine mimetics. However, no 
such molecules were found that bound to the protein by screening a small library of 
compounds.112 
 
Figure 3-5: Conformational changes of PD-1 when bound to PD-L1. 
A) PD-1 (blue) interaction with PD-L1 (green). Conformational changes shown by orange strands of 
apo PD-1. B) pocket formed by the conformational change of Tyr 68 and Glu 136. Image adapted 
from Zak et al. 2015.112 
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 Both nivolumab (BMS) and pembrolizumab (Merck) have been co-crystallized with 
PD-1.144, 145 Both antibodies bind to the PD-L1 binding site but occupy different 
neighboring regions of the protein. Nivolumab binds primarily to the FC and BC loops of 
PD-1. Pembrolizumab binds on the surface of the GFC strands in a similar fashion to PD-
L1. Pembrolizumab and PD-L1 interaction with many of the same residues (Figure 3-6, 
yellow). The shared residues are mostly hydrophobic and suggest a “hotspot” for binding 
of a small molecule. Highlighted interactions of PD-L1 with this hotspot is depicted in 
Figure 3-6D which includes the inducible pocket formed by Y68 and E136. While this site is 
 
Figure 3-6: PD-1 binding hotspot 
A) Overlay of co-crystal structures of PD-L1 (green) bound to PD-1 and pembrolizumab (blue) bound 
to PD-1. B) surface of PD-1 that interacts with PD-L1 (green) and pembrolizumab (blue) and the 
shared residues (yellow). C) electrostatic potential of PD-1 with residues involved in the interaction 
with PD-L1. D) PD-L1 residues in green sticks that interact PD-1 suggesting potential binding sites for 
small molecules. 
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of interest for binding of small molecules, binding to other sites may also disrupt the PD-
L1 interaction by an allosteric effect from dynamics of PD-1 protein in solution.  
3.2 Results 
3.2.1 Expression and purification of PD-1 
The extracellular domain of human PD-1 (residues 34 – 150) was cloned into the 
pET28b expression vector to contain a thrombin cleavable N-terminal 6-His tag and 
transformed into E. coli BL21 (DE3) cells. Uniformly 15N labeled PD-1 was expressed as 
inclusion bodies in M9 media containing 15N ammonium chloride after a 5 induction with 
IPTG at 0.8 OD600. Insoluble inclusion bodies were first purified by a series of Triton X-100 
and salt washing steps using centrifugation to pellet the inclusion bodies between steps. 
6His-PD-1 inclusion bodies were solubilized in 6M guanidine HCl and refolded dropwise 
into PD-1 refolding buffer. 6His-PD-1 was further purified and concentrated by loading to 
a nickel column. Eluted protein was dialyzed to remove imidazole and treated with 
thrombin to remove the 6xHis tag. PD-1 was separated from aggregated misfolded 
protein, the cleaved 6His tag, and thrombin by size exclusion chromatography (Figure 3-
7A). Purification of PD-1 resulted in highly pure protein with yields of 6 mg/L of 15N M9 
cell culture (Figure 3-7A-B). 
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3.2.2 Fragment screen of PD-1 
Screening conditions were optimized monitoring peak intensity in 1H-15N SOFAST 
HMQC spectra and adjusting the sample pH, salt concentrations, and protein 
concentration. Optimal conditions were found to be 0.27 mg/mL protein (20 µM) in 
buffer containing 50 mM Sodium Phosphate pH = 7 and 25 mM NaCl. All 13,824 
fragments in the library were screened by recording 1H-15N SOFAST HMQC spectra of 15N 
labeled PD-1 in the presence of mixtures of 12 fragments at 800 µM concentration each. 
 
Figure 3-7: PD-1 protein purification 
A) SDS PAGE gel of the PD-1 purification process. Lane 1: marker Lane 2: cell lysate prior to PD-1 
induction by IPTG. Lane 3: PD-1 expression induced by IPTG indicated by band at 16 kDa. Lane 4: 
Washed inclusion bodies (IB). Lane 5: Nickel affinity purification (IMAC) of refolded 6His-PD-1. Lane 
6: PD-1 with 6his tag removed by thrombin protease. Lane 7: Final purification step of size 
exclusion chromatography. B) Protein yields per liter of cell culture for each step of the purification 
process. C) HSQC of 15N labeled PD-1 indicates a well folded protein suitable for fragment 
screening. 
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A mixture sample was labeled as a “hit” if chemical shift changes were observed in 
fragment mixture samples relative to a sample containing only DMSO (Figure 3-8A). 
Deconvolution of the mixture screen resulted in 8 hits to PD-1 (hit rate = 0.05%, Figure 3-
8B). These hits have small resonance perturbations and weak binding affinity by HMQC 
titration experiments (> 2 mM) (Figure 3-8A). The fragment hits could be clustered into 
three main chemotypes. The first being a carboxylic acid bicyclic series, the second being 
 
Figure 3-8: Mapping fragment binding site to PD-1 
A) 1H-15N HMQC of a PD-1 fragment hit. Shifted residues are boxed in orange and labeled. B) 
Structures of the fragment hits identified to bind to PD-1. C) highlighted residues on the PD-1/PD-L1 
cocrystal structure shows the fragment binding site is distant to the PD-L1 binding site on PD-1. 
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an aromatic ring with a 6-8 atom flexible tail, and a third with saturated ring systems. All 
the fragments are highly polar and potentially make electrostatic interactions with PD-L1. 
 
Figure 3-9: Molecular modeling of PD-1 fragment hits 
Docking using Maestro Glide at the binding site defined by HMQC spectra of fragment hits. Ligand 
binding poses for all 8 hits are shown with hydrogen bonds shown as dotted lines 
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3.2.3 Molecular modeling of PD-1 hits and analog screening   
 Mapping the chemical shifts to the structure PD-1 using previously reported HSQC 
peak assignments suggest fragment hits bind to the AED strands of PD-1 (Figure 3-8). 
These residues form a shallow hydrophobic surface on the edge of T53 and T51 
neighbored by an electropositive area from R96 (Figure 3-9). The presence of an 
electropositive area is consistent with many of the hits containing carboxylic acids. 
However, attempts to generate X-ray co-crystal structures of the fragments bound to PD-
1 were unsuccessful.  
 
Figure 3-10: Analogs of PD-1 fragment hits screened. 
Analogs selected and screened from a substructure similarity search of Vanderbilt’s high throughput 
screening cores compound library. Each series of fragment is indicated by box color. 
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 To generate a model of how the fragments may bind to PD-1 to guide fragment 
SAR molecular docking experiments were utilized. Maestro InducedFit docking 
experiments were run to account for a high degree of flexibility seen electrophilic side 
chains, namely R96 which has high B-factors in PD-1 crystal structures. Docking results 
suggest fragments occupy a very shallow pocket between S109 and H107 and all but one 
fragment made electrostatic interactions with surrounding electrophilic residues. Notably, 
R96 was the most flexible residue in the docking experiments and forms hydrogen 
bonding interactions with fragments containing carboxylic acids and is predicted to form a 
cation-pi interaction with VU0239058. 
To further elaborate the SAR of the identified hits, a small set of analogs of 
VU0433121, VU0432776, VU0430144, and VU0239058 were ordered for screening. By 
substructure similarity searches of the compound library in the Vanderbilt High 
Throughput Screening Facility 49 compounds were screened (Figure 3-10). Most of the 
analogs did not bind to PD-1. Of the analogs that did bind, they had even smaller chemical 
shifts changes than the original fragment hits. SAR generated from the screen is 
consistent with the docking models, as many analogs remove hydrogen bonding 
interactions or place functional groups that are predicted to clash with the protein. 
However, no analogs were identified that were markedly better than the fragment hits 
identified in the large fragment screen. Furthermore, X-ray co-crystal structures of 
fragments bound would be useful to models to guide analog development as docking 
weakly binding fragments is highly speculative. 
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3.2.4 NMR-based PD-1 / PD-L1 displacement assay by NMR 
 Because the hits are predicted to bind on the opposite side of the PD-L1 binding 
site, large conformational changes would be required to disrupt binding to PD-1 via an 
allosteric effect. Large conformational changes in proteins are typically observed in HMQC 
spectra by the shifting of many peaks. However, fragment hits only shift select few of 
peaks. To validate this experimentally, all 8 PD-1 fragment hits were tested for the ability 
to disrupt the PD-1 / PD-L1 interaction using an NMR based assay antagonist induced 
dissociation assay (AIDA) (Figure 3-11). In the presence of unlabeled (14N) PD-1, PD-1 and 
PD-L1 form a complex causing a higher molecular weight complex that broadens the 
signal intensity of 15N PD-L1. If the fragment can interrupt the complex, the signal 
intensity of 15N PD-L1 is rescued. Addition of high molar excess (4 mM) of all 8 fragment 
hits of PD-1 failed to displace PD-L1. Either the fragments binding affinities are too weak 
to successfully displace the PD-1 PD-L1 interaction (~1 uM) or binding adjacent pocket 
fails to produce conformational changes that disrupt binding to PD-L1. 
3.3 Conclusions and Discussion 
 PD-1 is a highly validated target for cancer immunotherapy. Currently, antibodies 
that target PD-1 outnumber those that target CTLA-4 or PD-L1. Compared to the CTLA-4 
signaling pathway, PD-1 blocking antibodies have demonstrated higher response rates 
with fewer side effects.11 CTLA-4 and PD-1 are structurally similar and thus we expected 
PD-1 to be a challenging target for small molecules. Indeed, the fragment screen resulted 
in only 8 weak hits. The hit rate of 0.06% puts PD-1 in the “undruggable” category of 
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protein targets. These 8 hits bind with > 2 mM binding affinity and appear to bind on the 
opposite side of the PD-L1 binding site on PD-1. Furthermore, we were unable to 
generate co-crystal structures of these hits to confirm binding to this site. We found no 
 
Figure 3-11: PD-1 fragment hits fail to displace PD-L1 in solution. 
Displacement assay by 2D NMR experiments. Panel 1) HMQC of 15N labeled PD-1 alone. Panel 2) 
HMQC of equal molar concentrations of 15N PD-1 and unlabeled PD-L1 causes the formation of a 
higher molecular weight complex causing peak broadening. Panel 3) HMQC 15N PD-1, equal molar 
concentrations of unlabeled PD-L1, and 1 mM of PD-1 fragment hit. Failure to rescue signal 
intensity suggests the fragment hits do not displace the PD-1/PD-L1 interaction. 
PD-1 15N PD-L1
15N PD-L1
PD-1 15N PD-L1
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evidence that these fragments induce a large conformational change in the protein by 
HMQC spectra and saw no evidence that these fragments displace PD-L1 using an AIDA 
NMR assay. We also failed to generate fragment SAR by screening structurally similar 
analogs. 
 Taken together, these results indicate that, like CTLA-4, PD-1 is an extremely 
challenging target for small molecules. Despite the effort to find fragments that could 
serve as starting points for further optimization, the quality of hits were too weak and the 
lack of structural information of the fragments bound make it difficult to move forward. 
Additionally, if the optimization of the hits bound to this site was possible, these 
fragments are not likely to displace PD-L1 by an allosteric effect as evidence from the PD-
1 / PD-L1 AIDA assay. For these reasons, we concluded that PD-1 is undruggable by small 
molecules and shifted efforts to finding small molecules that bind to PD-L1 and disrupt 
this protein-protein interaction. 
3.4 Methods 
Cloning and expression tests 
 The extracellular domain of human PD-1 (residues 14 - 130) was cloned into the 
pET28b vector using NdeI and XhoI restriction sites to contain a thrombin cleavable N-
terminal 6His tag and transformed into E. coli DH5α cells (Thermo Fisher). Transformed 
cells were grown on kanamycin plates overnight at 37 ˚C. DNA of single colonies was 
isolated by miniprep DNA extraction and sequenced to ensure the correct ligation of the 
PD-1 into the expression vector. Small scale (10 mL) expression tests were performed 
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using colonies with correct plasmids. Overnight cultures consisting of LB with 50 ug/mL 
kanamycin and picking colonies on the kanamycin treated plate. Small aliquots of media 
(10 mL of LB + 50 ug/mL Kan) were inoculated with 100 µL of overnight culture to 10 mL 
cultures for expression tests (1% inoculation rate). Colonies with the highest level of 
expression in the expression tests (qualitatively determined by SDS PAGE gels) were used 
to make glycerol stocks stored at -80 ˚C.  
Protein production 
 Uniformly 15N labeled PD-1 was expressed as inclusion bodies in M9 minimal 
media containing 15N ammonium chloride. Protein production was induced with 1 mM 
IPTG at OD600 at 0.8 and harvested 5 hours later. The cell pellet was frozen at -80 C until 
needed for purification. Inclusion body purification was identical to methods described in 
Chapter 2 for CTLA-4 inclusion bodies. Purified PD-1 inclusion bodies were solubilized in 
50 mM Tris-HCl pH = 8.5, 250 mM, 6M Guanidine HCl for 4 hours at room temperature. 
PD-1 was refolded dropwise into PD-1 refolding buffer (50 mM HEPES pH 7.5, 24 mM 
NaCl, 1 mM KCl, 1 mM PMSF, 0.2 M arginine, 9 mM reduced glutathione, 1 mM oxidized 
glutathione) at 4 C overnight (12 – 16 hours). Refolded PD-1 was filtered through a 0.45-
micron filter and loaded to a NiNTA column using PD-1 refolding buffer as Buffer A and 
PD-1 refolding buffer + 500 mM imidazole as buffer B. Eluted PD-1 was pooled and 
dialyzed in PD-1 dialysis buffer (50 mM Tris pH = 7.5, 150 mM NaCl and 2 mM DTT). After 
8 hours of dialysis, thrombin was added to the dialysis buffer at 10 units/mg of protein to 
cleave the 6xHis-tag. Cleavage of the tag was monitored by SDS PAGE gel. After 100% of 
the tag had been cleaved, PD-1 was concentrated to 1 mg/mL using a stirred amicon 
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under nitrogen pressure using a 5 kDa molecular weight cutoff. Concentrated PD-1 was 
loaded to a size exclusion column (Superdex76 26/60) pre-equilibrated with NMR buffer 
(50 mM Sodium Phosphate pH = 7 and 25 mM NaCl). Purification of unlabeled protein for 
PD-L1 displacement assay was identical to the described method but with LB media 
instead of M9 media. 
Fragment Screening 
NMR screening was performed at 30 °C using a Bruker Avance III 600 MHz 
spectrometer equipped with a 5 mm single-axis z-gradient cryoprobe and Bruker 
SampleJet sample changer. Screening samples (500 µL) screened contained 30 µM of 15N 
PD-1, 12 fragments at 800 µM each, and 5% DMSO-d6. 1H,15N SOFAST-HMQC spectra 
were obtained using 20 scans and analyzed using Topspin (Bruker BioSpin). Deconvolution 
of hit mixtures was performed as a single fragment at 800 µM concentration. PD-1 
proteins were able to be recycled by filtering through a 0.45 μm filter and loading to a 
buffer exchange column. 
Docking and substructure similarity searching. 
 Maestro (Schrodinger) was used for all molecular modeling. The human PD-1 
crystal structure (PDB ID: 3RRQ) protein was prepared for modeling by adding missing 
side chains/residues, charged in pH 7 buffer, and energy minimized by the Protein Prep 
Wizard. A docking grid was generated around amino acids identified in the fragment 
screen for binding. All 8 of the fragment hits were imported as SD files and prepared for 
ligand docking using Ligprep. Fragments were docked using Glide with normal settings 
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and extra precision. Substructure searching was performed by searching the Vanderbilt 
high throughput screening core’s compound library using ChemCart. Substructure 
searches included placement of heteroatoms in the core rings and allowing multiple 
substitutions off the core ring structure. 
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Chapter 4 
Fragment Screen of Programmed Death Ligand-1 (PD-L1) 
4.1 Introduction 
4.1.1 PD-L1 is a validated target for cancer immunotherapy 
 In the context of cancer, the primary binding partner of PD-1 is PD-L1. PD-L1 is 
normally expressed on somatic cells in response to pro-inflammatory cytokines as a 
defense mechanism against autoreactive T cells. However, PD-L1 is also found to be 
upregulated in many cancer types by oncogenic activation of PD-L1 transcription factors.17 
PD-L1 expression on tumor cells results in PD-1 mediated inactivation of tumor targeting T 
cells in the tumor microenvironment and is thought to be the primary mechanism cancer 
cells use to evade the immune response.11 Therapeutic antibodies that target either PD-1 
and PD-L1 have been developed remove this evasion mechanism and both have been 
successful at generating antitumor responses in clinical trials.146  
 Targeting PD-L1 is thought to offer some potential advantages compared to 
targeting PD-1.147 Antibodies that target PD-1 block the interaction with both PD-L1 and 
PD-L2. PD-L2 has been shown to be an important regulator of autoimmunity in lung tissue 
and downregulates T helper-2 (Th-2) cells that promote tumor development.148 Given that 
PD-L2 is only expressed in the minority of human cancers, leaving PD-L2 un-inhibited with 
PD-L1 inhibitors might mediate autoimmunity in certain tissues.149 Indeed, clinical trials 
with PD-1 antibody compared to PD-L1 noted a slightly higher incidence of irAEs and 
drug-related pneumonitis.150, 151 Antibodies targeting PD-L1 entered clinical trials in 2011, 
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5 years after the first PD-1 antibodies entered the clinical. Three PD-L1 antibodies are 
currently FDA approved as monotherapy in a total of four different cancer types including 
urothelial cancer, non-small cell lung cancer, bladder cancer, and Merkel cell carcinoma.17  
4.1.2 PD-L1 structure and function 
 PD-L1 is a type I transmembrane protein consisting of IgV and IgC domains in the 
extracellular region. PD-L1 contains two disulfide bonds, one in the IgV domain (C40 – 
C114) and one in the IgC domain (C155 – C209). Co-crystal structures suggest the IgV 
domain of PD-L1 is the sole interaction domain with PD-L1 (Figure 4-1 A). PD-L1 is N-
glycosylated at 3 asparagine residues in the IgC domain (N192, N200 and N219) and 1 
asparagine residues in the IgV domain (N35, Figure 4-1 B ).112 Notably, N-glycosylation of 
the IgC domain plays an important role in the regulation of PD-L1.152 Un-glycosylated PD-
L1 interacts with GSK3B forming a complex with B-trCP that induced phosphorylation-
dependent proteasome degradation of PD-L1.152 However, N35 glycosylation in the IgV 
domain does not play a role in effecting PD-L1 stability.152 N35  is on the opposite face of 
PD-L1 from the PD-1 binding site and is not expected to alter binding to PD-1. Unlike PD-1, 
PD-L1 lacks traditional signaling motifs in the cytosolic region of the protein and is not 
expected to be a signaling molecule. However, recent reports suggest that non-classical 
conserved motifs in the PD-L1 cytolytic region may protect cells from interferon-mediated 
toxicity which is thought to aid in immune evasion.153 Elucidating the diverse functions of 
PD-L1 is currently an active area of research and will contribute a greater understanding 
of the tumor-promoting function of PD-L1. 
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4.1.3 PD-L1 binding hotspot for small molecules 
 Numerous co-crystal structures of PD-L1 bound to ligands have been reported in 
the literature. In addition to the human PD-1 / human Pd-L1 co-crystal structure, four 
clinically used monoclonal antibodies have also been determined.154 These structures 
have yielded valuable information of potential hot spots of binding to PD-L1. Indeed, PD-1 
 
Figure 4-1: Structure of the extracellular portion of PD-L1.  
A) PD-L1 (rainbow) bound to PD-1 (gray). The extracellular portion of PD-L1 consists of an IgV and 
IgC domain. PD-1 interacts with only the IgV domain of PD-L1. B) PD-L1 IgV domain strands labeled 
with disulfide bonds and glycosylation site (N35) highlighted. C) Multiple sequence alignment of 
human and mouse PD-L1. Identical residues (red), conserved residues (blue), differing residues 
(black), and residues that interact to form the PD-1/PD-L1 complex (asterisks) are shown. 
Glycosylation sites are labeled by triangles, cysteines in disulfide bonds are labeled by circles and 
the free cysteine residue mutated to serine is labeled by a star. Image adapted by Lin et al. 2008. 155 
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and all four antibodies occupy a similar hydrophobic core on PD-L1 (Figure 4-2A, yellow 
surface). This core consists of five hydrophobic resides I54, Y56, M115, A121, and Y123 
(Figure 4-2B). Interestingly, all antibodies occupy different surrounding electrostatic 
regions outside of the hydrophobic core (Figure 4-2A, colored surfaces). These structural 
insights suggest this hydrophobic core to be a potential hotspot for small molecule to 
bind and disrupt the interaction with PD-1. However, the surface at this site is mostly flat 
 
Figure 4-2: PD-L1 hotspot for small molecule binding. 
A) Mapping the binding of PD-1 and anti-PD-L1 antibodies to PD-L1. Colored surface indicates 
binding surface of the PD-L1. Yellow surface is the shared region between PD-L1 and anti-PD-L1 
antibodies. B) Electrostatic map of the shared binding site on PD-L1 highlights the hydrophobic 
pocket C) Specific interactions PD-1 makes at the hotspot suggesting potential binding sites for 
small molecules. Image adapted by Zak et al. 2017. 154 
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with one shallow pocket formed by Y123 and R113 where PD-1 inserts an isoleucine 
residue (Figure 4-2C).  
4.2 Results 
4.2.1 PD-L1 construct optimization 
The first PD-L1 construct tested consisted of both IgV and IgC domains (1 – 239, 25 
kDa). This construct was cloned into the pET28b expression vector to contain a thrombin 
cleavable N-terminal 6His tag to aid in purification. This construct was expressed as 15N 
labeled protein and purified according to previously reported protocols.155 The 1H-15N 
HMQC spectra of this construct was missing approximately 100 peaks, contained many 
poorly resolved peaks and had varying peak intensities which would complicate data 
analysis for screening (Figure 4-3A). Buffer optimization, the addition of an anion 
exchange purification step, and modifications of the N-terminus failed to improve the 
quality of the HMQC spectra. Given that the IgV domain is the sole interaction domain for 
PD-L1, constructs of the IgV domain alone (18 – 132) were designed to improve the 
HMQC spectrum. However, attempts to express and purify these constructs resulted in 
protein that was not stable at concentrations required for NMR experiments (> 15 µM). 
Like the construct with both domains, the spectrum of the IgV domain at 10 µM with 
longer scan times is also missing numerous peaks (Figure 4-3B). 
Because both PD-L1 constructs needed to be refolded, we speculated that the fold 
of the protein was incorrect. To express soluble protein from E. coli, we did expression 
tests with special Shuffle E. coli (NEB) strains that have been engineered to have a 
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reducing cytosol and correctly fold proteins with disulfide bonds. To further promote the 
proper folding of PD-L1 in the cytosol, we engineered a fusion construct with the 
chaperone protein thioredoxin.156 We also engineered PD-L1 fusion constructs with 
solubilizing proteins such as MBP and GST. Expression tests constructs containing 
thioredoxin, MBP, or GST fusion proteins resulted in a small fraction (estimated < 5%) of 
the PD-L1 fusion to be expressed as soluble protein. However, cleaving the MBP or 
Thioredoxin fusion from the IgV domain resulted in significant protein aggregation seen in 
previous refolded constructs.  
 
Figure 4-3: Preliminary PD-L1 constructs HMQC Spectra 
PD-L1 constructs containing both IgV and IgC domains (left) and only the IgV domains (right) with 
HMQC spectra of each construct. 
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With no success in expression with fusion partners, other strategies were utilized 
to enhance the stability of the IgV domain. These strategies included adding purification 
tags at both N and C termini, extensions and truncations at both termini and rational 
design of mutations (Figure 4-4). The PD-L1 construct (18 – 132) was first modified by 
engineering mutations of solvent-exposed residues that were distant to the PD-1 binding 
site to increase the solubility and/or the stability of the protein (Figure 4-5A). Many of 
these mutations were designed by computational methods using protein engineering 
tools in Maestro modeling software developed by Schrödinger. Solvent-exposed 
hydrophobic residues were mutated to charged residues to remove potential aggregation
 
Figure 4-4: Construct optimization overview 
Flow chart of the diverse strategies taken to optimize the PD-L1 IgV protein stability. 
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Figure 4-5: Construct design to improve protein stability. 
A) Mutations made on the IgV domain distant from the PD-1 binding site (Teal). Orange 
residues are hydrophobic residues mutated to charged residues. Red residues are charged 
residues that were mutated to adjust the pI of the protein. Green residues are computationally 
predicted to enhance protein stability. B) C-terminal extensions into the IgC domain. Each label 
indicates a stop codon at the specific amino acid number. C) Disulfide engineering of PD-L1 
(gray) based on homology to CTLA-4 (orange). Residues that were mutated to cysteines in pairs 
are indicated by green sticks and labeled. 
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sites (Figure 4-5A, orange surface). Charged residues were mutated to opposite charges 
to alter the pI of the construct (wildtype pI = 6.3) (Figure 4-5A, red surface). Additionally, 
Amanda Duran in Dr. Jens Meiler’s lab at Vanderbilt University used Rosetta Protein 
Design to predict residues that lower the folding energy and increase protein stability. 
Rosetta suggested that residue valine 76 be mutated to lysine and alanine 98 be mutated 
to arginine for increases in protein stability (Figure 4-5A, green surface).  
Mutations were tested in small scale productions and effects on stability were 
quantified by noting the max concentration that the construct was able to achieve before 
precipitating out of solution. Despite the variety of different mutations made, only minor 
effects on the stability were observed. Combinations of beneficial mutations resulted in 
constructs that were much worse than the wildtype or single mutation constructs. 
Because mutants had little benefit on protein stability, we hypothesized that other 
aspects of the construct were causing instability of the IgV domain.   
The N and C termini were modified next to explore other modifications that may 
affect stability. Like the PD-L1 construct containing an IgV and IgC domain, extending or 
shorting the sequence at the N-terminus resulted in no effect on the protein stability. 
Short extensions or deletions at the C-terminus also had no effect. However, longer C-
terminal extensions into the IgC domain resulted in significant improvements in stability. 
A series of constructs were designed that extended 28 residues into the IgC domain 
(Figure 4-5B, purple cartoon). The best construct contained a stop codon at residue 149. 
The HMQC spectra of the IgV-149 construct had disperse peaks, good signal intensity and 
the protein was stable to 1.5 mg/mL in the presence of 4% DMSO. However, the addition 
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of fragment mixtures (12 fragments at 800 µM each) to this construct rapidly aggregated 
as monitored by disappearance of HSQC signal intensity and visually by protein 
precipitation. Extensive buffer optimization and reduction of the concentration of 
fragments in the mixture failed to improve the protein stability.  
Reflecting on previous work, CTLA-4 was highly stable when conducting a 
fragment screen. Given that CTLA-4 and PD-L1 both share IgV type folds, the structures of 
both proteins were overlaid to identify potential structural differences that may enhance 
PD-L1 stability (Figure 4-5C). Overlay of CTLA-4 and PD-L1 structures reveal identical 
placement of the canonical IgV fold disulfide bond (Figure 4-5C, orange and gray sticks). 
CTLA-4 has a second disulfide bond that could explain the enhanced construct stability 
compared to PD-L1. The overlay of both structures identified residues on PD-L1 that could 
be mutated to cysteine to mimic CTLA-4’s additional disulfide bond. Modeling of potential 
disulfide bonds was performed using a web-based server Disulfide by Design 2 to predict 
potential disulfide bond formation based on the proximity and geometry of two residues 
if mutated to cysteine residues. Using these predictions, another four potential disulfide 
bonds were tested. However, mutations of these residues to cysteine severely interfered 
with protein refolding during purification. The small percentage of soluble protein after 
refolding was found to consist of large disulfide-linked aggregates on SDS PAGE gels and 
size exclusion chromatography.  
Shortly after our discovery that the C-terminus is important for the stability of the 
IgV domain, two PD-L1 IgV constructs purified from E. coli were reported in the 
literature.112, 157 The first report added 8-arginine residues after residue 132 to increase 
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the solubility of the protein.157 To reproduce this result we designed and tested both PD-
L1 8-arginine and PD-L1 8-lysine constructs. In addition to positively charged tags, a PD-L1 
S-tag construct was designed to add charged residues without altering the pI of the 
protein. While the 8-arginine construct was found to be toxic to E. coli cells, both the 8-
lysine and Stag constructs were expressed and purified in high yields and resulted in high-
quality HMQC spectra. While improved over the previously discovered IgV-149 construct, 
both IgV-8Lys and IgV-Stag were also unstable when mixing with fragment mixtures 
required for NMR screening.  
The second literature report was an IgV construct with a non-cleavable C-terminal 
6His tag after residue 132.112 The published crystal structure of this construct reveals the 
6His tag adapts alpha-helical secondary structure and folds back on the IgV protein 
 
Figure 4-6: Design of H140E mutation on IgV-6His construct 
A) Crystal structure of the IgV-6His construct with highlighted interactions from the 6His tag with 
the IgV domain. Hydrogen bonds are shown by yellow dashed lines. Surface is transparent 
electrostatic potential of the protein suggesting an electropositive region from K105. B) Overlay of 
IgV-6His and IgV-6His-H140E mutant show hydrogen bond formation of E140 with backbone 
amides of the IgV domain. Conformational changes of Q107 and Y32 were also identified. Q107 
forms additional hydrogen bonding networks suggesting structural information of the enhanced 
stability of this construct. Image adapted from Perry et al 2019.172 
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forming both hydrophobic and electrostatic interactions (H140-H142) with the IgV 
domain (Figure 4-6A). This construct was expressed and purified in our lab but also found 
to be unstable with fragment mixtures. Using the structural information of the helix 
interacting with the IgV domain, mutations were rationally designed that could further 
enhance the stability. Notably, a large electropositive region of the protein formed by 
K105 and Q107 appeared to be in closest contact to the 6His portion of the helix. 
Molecular modeling experiments suggested mutation of H140 to glutamic acid could form 
additional hydrogen bonds with this region (Figure 4-6A). The IgV-6His-H140E construct 
was purified and crystallized in similar conditions to the reported wildtype construct. 
Indeed, the structure reveals E140 forms additional hydrogen bonding interactions with 
back amides of 106 and Q107 (Figure 4-6B). 
 
Figure 4-7: PD-L1 IgV-6His is properly folded and binds to PD-1 
A) Overlay of the IgV portion of the IgV-IgC crystal structure (gray) with the mutant construct (IgV-
6His-H140E, yellow) show an identical fold of the protein suggesting the mutation does not interfere 
with the fold of the protein. B) Overlay of HMQC spectra of 15N IgV-6his-H140E (blue) and equimolar 
concentrations of unlabeled PD-1 added to 15N IgV-6his-H140E results in peak shifts and peak 
broadening indicating binding of PD-1 to mutant construct suggesting the mutant is functionally 
active. 
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Table 4-1: List of all PD-L1 constructs designed and tested 
 
 
Construct Name Sequence
Removable 
Tag Plasmid
IgV-IgC
IgV-IgC-12 12-239 none pET29
IgV-IgC-16 16-239 none pET29
IgV-IgC-18 18-239 none pET29
6His-IgV-IgC 18-239 N-term 6His pET28b
GST-IgV-IgC 18-239 N-term GST pGEX6-1
Trx-IgV-IgC 18-239
N-term 6His-
Trx-Stag pET32a
IgV-IgC-6His 18-239 none pET29
IgV-IgC-N-modified 18-228 N-term 6His pET28b
MBP-IgV-IgC 18-228 N-term MBP pAT108
IgV-IgC-MBP 18-228 C-term MBP pAT108
SUMO-IgV-IgC 18-228 N-term SUMO pBG102
IgV-IgC-SUMO 18-228 C-term SUMO pBG102
IgV Purification Tags
IgV 18 - 132 none pET29
6his-IgV 18 - 132 N-term 6His pET28b
GST-IgV 18 - 132 N-term GST pGEX6-1
Trx-IgV 18 - 132
N-term 6His-
Trx-Stag pET32a
MBP-IgV 18 - 132 N-term MBP pAT108
IgV-MBP 18 - 132 C-term MBP pAT108
SUMO-IgV 18 - 132 N-term SUMO pBG102
IgV Mutants
IgV-D26K 18 - 132 N-term 6His pET28b
IgV-L27K 18 - 132 N-term 6His pET28b
IgV-V29K 18 - 132 N-term 6His pET28b
IgV-Y32K 18 - 132 N-term 6His pET28b
IgV-N35D 18 - 132 N-term 6His pET28b
IgV-N35E 18 - 132 N-term 6His pET28b
IgV-E39K 18 - 132 N-term 6His pET28b
IgV-E39A 18 - 132 N-term 6His pET28b
IgV-E39S 18 - 132 N-term 6His pET28b
IgV-K41A 18 - 132 N-term 6His pET28b
IgV-K41S 18 - 132 N-term 6His pET28b
IgV-V44K 18 - 132 N-term 6His pET28b
IgV-L50Y 18 - 132 N-term 6His pET28b
IgV-L50M 18 - 132 N-term 6His pET28b
IgV-E71K 18 - 132 N-term 6His pET28b
IgV-L74K 18 - 132 N-term 6His pET28b
IgV-V76K 18 - 132 N-term 6His pET28b
IgV-Q91A 18 - 132 N-term 6His pET28b
IgV-Q91S 18 - 132 N-term 6His pET28b
IgV-Q91K 18 - 132 N-term 6His pET28b
IgV-L94K 18 - 132 N-term 6His pET28b
IgV-A98R 18 - 132 N-term 6His pET28b
IgV-D103K 18 - 132 N-term 6His pET28b
IgV-L106K 18 - 132 N-term 6His pET28b
IgV-E39K,V44K 18 - 132 N-term 6His pET28b
IgV-V76K,A98R 18 - 132 N-term 6His pET28b
IgV-V76K,L94K 18 - 132 N-term 6His pET28b
IgV-E71K,L106K 18 - 132 N-term 6His pET28b
IgV-E71K,L94K 18 - 132 N-term 6His pET28b
IgV-L94K,L106K 18 - 132 N-term 6His pET28b
6His-IgV-D26K, V76K 18 - 132 N-term 6His pET28b
6His-IgV-D26K, L94K 18 - 132 N-term 6His pET28b
6His-IgV-V76K, K41S, 
Q91S 18 - 132 N-term 6His pET28b
6His-IgV-D26K, V76K, 
L94K 18 - 132 N-term 6His pET28b
Surface hydrophobic 
Residues Construt 1 18 - 132 none pET28b
Surface hydrophobic 
Residues Construt 2 18 - 132 none pET28b
Construct Name Sequence
Removable 
Tag Plasmid
IgV Truncations
IgV-136 18 - 136 N-term 6His pET28b
IgV-139 18 - 139 N-term 6His pET28b
IgV-146 18 - 146 N-term 6His pET28b
IgV-149-N 18 - 149 N-term 6His pET28b
IgV-149a 18 - 149 N-term 6His pET28b
IgV-149b 18 - 149 N-term 6His pET28b
IgV-155 18 - 155 N-term 6His pET28b
IgV-160 18 - 160 N-term 6His pET28b
IgV-Loop del-
P43/V44; delL50; 
delA51; del L53; del 
L50A51 18 - 132 N-term 6His pET28b
IgV-149-D26K 18 - 149 N-term 6His pET28b
IgV-149-L94K 18 - 149 N-term 6His pET28b
IgV-149-V76K 18 - 149 N-term 6His pET28b
Charged C-terminal Tags
IgV-8Arg 18 - 132 N-term 6His pET28b
IgV-Stag 18 - 132 N-term 6His pET28b
IgV-8Lys 18 - 132 N-term 6His pET28b
IgV-8Lys-6His 18 - 132 N-term 6His pET28b
IgV-8Lys-6His-6His 18 - 132 N-term 6His pET28b
IgV-8Lys-V76K 18 - 132 N-term 6His pET28b
IgV-8Lys-V76T 18 - 132 N-term 6His pET28b
IgV-8Lys-V76G 18 - 132 N-term 6His pET28b
N-2Lys-IgV-8Lys 18 - 132 N-term 6His pET28b
N-4Lys-IgV-8Lys 18 - 132 N-term 6His pET28b
Disulfide Bond Engineering
6His-IgV-I64C, A85C 18 - 149 N-term 6His pET28b
IgV-8Lys-I64C,A85C 18 - 132 N-term 6His pET28b
IgV-8Lys-I65C,A85C 18 - 132 N-term 6His pET28b
IgV-8Lys-G33C,D103C18 - 132 N-term 6His pET28b
IgV-8Lys-N35C, 
T102C 18 - 132 N-term 6His pET28b
IgV-8Lys-S34C,V104C 18 - 132 N-term 6His pET28b
C-terminal 6His Tag
IgV-6His 18 - 132 none pET28b
IgV-6His-V76G 18 - 132 none pET28b
IgV-6His-V76T 19 - 132 none pET28b
IgV-6His-Y136D 18 - 132 none pET28b
IgV-6His-H140E 18 - 132 none pET28b
IgV-6His-8Lys 18 - 132 none pET28b
IgV-6His-8Lys-V76K 18 - 132 none pET28b
IgV-6His-6His 18 - 132 none pET28b
IgV-6His-4His-6His 18 - 132 none pET28b
IgV-8His 18 - 132 none pET28b
SUMO-IgV-6His 18 - 132 N-term SUMO pBG102
MBP-IgV-6His 18 - 132 N-term MBP pAT108
Constructs for X-ray Crystallography
IgV-6His-V76T,H140E 18 - 132 none pET28b
IgV-IgC-STOP228 18-228 none pET29
IgV-6His-R113A 18 - 132 none pET28b
IgV-6His-E58A 18 - 132 none pET28b
IgV-6His-L27N 18 - 132 none pET28b
IgV-6His-L50Y 18 - 132 none pET28b
IgV-6His-L50M 18 - 132 none pET28b
IgV-6His-L74N 18 - 132 none pET28b
IgV-6His-A51D 18 - 132 none pET28b
IgV-MBP 18 - 132 none pET28b
IgV-Lysozyme 18 - 132 none pET28b
70 
 
 
Unexpectantly, the H140E mutation caused a conformational change of Q107 to rotate up 
towards PD-L1 and form additional hydrogen bonding network with S80, R84, and D108 
(Figure 4-6B). This mutation significantly improved the stability of the IgV domain during 
purification and with the addition of fragments. The H140E mutation did not cause any 
other conformational changes to the protein that would cause differences in the fold of 
the IgV domain relative to wildtype (Figure 4-7A).  
To further validate the mutation did not alter protein function, the IgV-6his-H140E 
construct was shown to retain binding to PD-1 by monitoring resonances shifts and 
resonance broadening in 1H-15N HMQC spectra of IgV-6his-H140E with the addition of 
equimolar concentrations of unlabeled PD-1 (Figure 4-7B). With increased stability and 
validation that this construct retained the ability to bind PD-1, this construct was used for 
fragment screening. Summary of all constructs designed and tested for the optimization 
of PD-L1 stability is outlined in Table 4-1. 
4.2.2 Expression and purification of PD-L1 
Large amounts of 15N labeled protein was produced to conduct the fragment-
based screen. This plasmid containing the IgV-6His-H140E construct was transformed into 
E. coli BL21 (DE3) cells (Thermo Fisher). Uniformly 15N labeled PD-L1 was expressed as 
inclusion bodies in M9 media containing 15N ammonium chloride after a 5-hour induction 
with IPTG at 0.8 OD600. Insoluble inclusion bodies were first purified by a series of Triton 
X-100 and salt washing steps using centrifugation to pellet the inclusion bodies between 
steps. PD-L1 inclusion bodies were solubilized in 6M guanidine HCl and refolded dropwise 
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into PD-L1 refolding buffer containing 1M Arginine. Refolded PD-L1 was dialyzed in large 
volumes (2L protein to 8L of buffer) of dialysis buffer 3 times for 24 hours per dialysis step 
to reduce the concentration of arginine. Unlike PD-1 and CTLA-4, PD-L1 was not 
concentrated by nickel affinity purification due to protein aggregation observed on the 
column. Instead, PD-L1 was concentrated using Amicon stirred cells using a 5 kDa 
molecular weight cut off membrane.  PD-L1 at 0.5 mg/mL concentration (30 µM) was 
further purified by size exclusion chromatography preequilibrated with NMR buffer 
 
Figure 4-8: PD-L1 protein production summary 
A) SDS PAGE gel of the PD-L1 purification process. Lane 1: marker Lane 2: cell lysate prior to PD-L1 
induction by IPTG. Lane 3: PD-L1 expression induced by IPTG indicated by band at 14 kDa. Lane 4: 
Washed inclusion bodies (IB). Lane 5: concentrated refolded PD-L1. Lane 6: PD-L1 after size 
exclusion. B) Protein yields per liter of cell culture for each step of the purification process. C) HSQC 
of 15N labeled PD-L1 indicates a well folded protein suitable for fragment screening. 
 
Purification step Protein 
Recovered
Yield (%)
Washed IBS 1.25 g N/D
Denatured IBS 98 mg 100
Refolded PD-L1 43 mg 43
Size Exclusion 20 mg 20
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(Figure 4-8A). Purification of PD-L1 resulted in highly pure protein with yields around 30 
mg/L of 15N M9 cell culture (Figure 4-8B). 
4.2.3 Fragment Screen of PD-L1 
Screening conditions were optimized by adjusting the buffer pH, salt 
concentration, fragment concentrations and the number of fragments per mixture. A test 
set of 30 diverse fragments handpicked from the fragment library were used to assess 
protein stability in the presence of fragment mixtures. The goal of the optimization was to 
achieve a minimum of 8 hours of protein stability at room temperature when mixed with 
fragments monitored by HMQC signal intensity at room temperature. Optimized 
conditions were found containing 50 mM Sodium Phosphate pH = 7, 25 mM NaCl with 4% 
DMSO. PD-L1 was found to be stable for 8 hours containing mixtures of 6 fragments at 
400 µM each. The Fesik lab fragment library containing 13,824 fragments was screened by 
monitoring chemical shift changes in 1H-15N SOFAST HMQC spectra of 15N labeled PD-L1 in 
optimized screening conditions as mixtures of 6 fragments. Hits in mixture samples were 
noted by chemical shift changes and/or peak broadening relative to a DMSO sample. 
Mixture samples marked as hits were deconvoluted by testing each fragment individually 
at 800 µM concentration. In total, the screen resulted in the identification of 226 
fragments that bind to PD-L1. All hits to PD-L1 are shown in Appendix A.  
4.2.4 Hit classes from fragment screen 
Three types of HMQC spectra were observed in the screen (Figure 4-9). 40% of the 
hits had resonance shifts traditionally seen in fast exchange binding, termed class A hits. 
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(Figure 4-9A). 38% of hits had specifically broadened peaks, termed class B (Figure 4-9 B) 
and the remaining 22% of hits had uniformly broadened peaks typically associated with 
protein oligomerization or aggregation, termed class C (Figure 4-9C). Notably, the 
resonances that shift in class A are the same peaks that broaden in class B (Figure 4-9, 
orange boxes). 
 Broadening of specific peaks could be indicative of intermediate exchange binding 
(Kd < 10 µM). The peak intensity of a broadened peak is typically brought back at when 
protein is saturated with ligand at concentrations many fold higher than the Kd. To test if 
these fragments bind to PD-L1 with low micromolar affinity, fragments were titrated 
using high concentrations of fragments (up to 1.6 mM). However, fragments at high 
concentrations failed to bring any signal back from broadened peaks suggesting these hits 
may not be due to intermediate exchange binding (Figure 4-10A). Peak broadening may 
also be caused by minor protein precipitation. However, removal of fragments from the 
 
Figure 4-9: Hit classes identified in the fragment screen. 
Class A hits classified by peak shifts. Class B hits classified by specific peak broadening. Class C hits 
classified by universal peak broadening. Class A and Class B hits resulted in changes in the same 
peaks, suggesting these fragments are interacting with the same pocket on PD-L1. Resonance 
broadening verses shifting is likely due to protein dynamics on the intermediate time scale.  
Class BClass A Class C
86 Hits91 Hits 49 Hits
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sample by dialysis overnight and re-running a HMQC on the dialyzed sample resulted in 
the rescue of the signal intensity of broadened peaks (Figure 4-10B), suggesting that 
broadening of class B hits are fragment specific. From these studies, we hypothesized that 
these hits may be due to protein dynamics or conformational changes in the protein 
caused by fragment binding. Indeed, a co-crystal structure obtained of class B hits later in 
this chapter suggest broadening seen from these hits is due to protein dimerization. 
 
Figure 4-10: Class B hit validation 
A) HMQC of a class B hit. Black line indicates the 1D extracted slide at 126.8 ppm. 1D slide 
extracted at 126.8 ppm 15N of a titration of a class B hit shows only peak 1 results in a dose 
dependent broadening suggesting broadening is dependent on ligand concentration. B) Dialysis 
experiment of class B hit. HMQC spectra obtained of a class B hit (left). Sample is then removed 
from the NMR tube and dialyzed overnight to remove fragment. Sample is added back to an NMR 
tube and HMQC spectra is obtained (right). Rescue of signal intensity is suggesting broadening is 
ligand dependent and not resulting from artifacts like protein aggregation. 
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Class C hits that have universal peak broadening are typically dismissed in a 
fragment screen as compounds that cause protein aggregation or denaturation. Class C 
mixtures were also deconvoluted in case a fragment hit was contained in one of these 
mixtures that would otherwise be missed. Many class C hits in fragment mixture samples 
failed to produce a hit during deconvolution. Interestingly, deconvolution of class C hits 
identified 49 fragments that caused universal peak broadening. These fragments were 
found to be time-dependent, failed to rescue peak intensity after dialysis, and eluted as 
protein aggregates on size exclusion chromatography experiments.  These hits were not 
followed up for structure determination and medicinal chemistry efforts.  
4.2.5 Fragment hit titrations 
Qualitative V-scores were given to each fragment mixture and deconvoluted hit. 
V-scores were on a scale of 0 to 4 with 0 indicating no speak shifts or broadening, 1 
indicating weak shifts or broadening and 4 indicating strong shifts or broadening. 
However, V-scores do not always correlate with higher binding affinity due to the 
different shielding or de-shielding potential of the fragments. Thus, to accurately rank 
order hits based on the affinity to PD-L1, Kd values were generated by NMR titration 
experiments for class A hits (Figure 4-11A). NMR titrations were conducted using a 6-
point curve with 2-fold serial dilutions starting at 1.6 mM as the top concentration. 
Preliminary titrations of Class A hits were weak and failed to saturate the binding curve. 
To accurately measure Kd values the top fragment concentration was raised to 3 mM. 
However, many fragments were not soluble at concentrations above 1 mM and 
processing data without accounting for the fragment solubility yielded inaccurate Kd 
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estimates. To account for fragment solubility a 1D proton spectrum was taken 
immediately prior to a 2D HMQC spectra. The signal intensity of a singlet peak in a 1H 
spectra was plotted against the fragment concentration (Figure 4-11B). The signal 
intensity of a singlet peak is proportional to the fragment concentration and thus a 
plateau in signal intensity indicates the fragment solubility limit has been reached. Any 
 
Figure 4-11: NMR Titrations of fragment hits 
A) Overlay of HMQC of a fragment titration at 30 µM PD-L1. Fragment concentration is color 
coded based on peak color. B) Overlay of a singlet peak obtained from 1H NMR spectra from a 
fragment titration (left). Plot of the signal intensity verses compound concentration (right) shows 
a linear relationship suggesting the compound is soluble to 3 mM. C) Peak shifts in ppm verses 
compound concentration used to calculate Kd values of fragment hits. 
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data points with poor solubility were excluded from titration data processing. 
Furthermore, if the Kd from a titration curve was predicted to be higher than the top 
concentration of the titration (3 mM) then the Kd was simply noted as > 3 mM. The Kd 
values obtained for class A hits with a V-score greater than 1 ranged from 1 mM to 
greater than 3 mM. Class B hits were not titrated due to the inaccuracies of Kd 
determination by plotting peak intensities of broadened peaks vs compound 
concentrations.158 
Only one shifting and broadening pattern was identified from the screen 
suggesting that all hits bind to the same location on PD-L1. The assignments of the PD-L1 
HSQC spectra have not been reported to date. Shifted residues that are highlighted by 
orange boxes were assigned by mutagenesis (Figure 4-12A). These residues map to the 
PD-1 binding site of PD-L1 and suggest that fragment hits bind to this site (Figure 4-12B). 
 
Figure 4-12: Fragment hits bind to the PD-1 binding site of PD-L1 
A) Overlay of HMQC spectra of PD-L1 IgV-6His-H140E (blue) with PD-L1 with a fragment hit (red). 
Peaks in orange boxes and labels are assigned residues based on partial assignments of PD-L1. B) 
Co-crystal structure of the PD-1 / PD-L1 interaction. Boxed peaks are highlighted by orange 
surface on the PD-L1 surface suggesting the fragments bind to the PD-1 binding site on Pd-L1. 
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4.2.6 NMR displacement Assay 
To test if the fragment hits were capable of displacing PD-1 from PD-L1 an NMR 
based antagonist induced dissociation assay (AIDA) was utilized.159 The AIDA assay was 
performed by the addition of a slight molar excess of unlabeled PD-L1 to 15N PD-1 causing 
HMQC signals to broaden corresponding to complex formation (Figure 4-13B). Addition of 
fragments that displace 15N PD-1 from PD-L1 result in a rescue of the 15N PD-1 signal 
(Figure 4-13C).  
In total, 104 of the top fragment hits were tested in this assay and given a score 
based on the percentage of peak intensity rescued by the addition of the fragment. 
Fragments were ranked based on their ability to rescue the signal intensity of glycine 90 
of PD-1 at 800 µM fragment concentration (Figure 4-14). The best hits were assigned a 
score of 2 that displayed > 15% rescued signal. Hits that were between 1% and 15% were 
given a score 1 and hits that failed to displace PD-1 were scored 0. In total, 36 of the 
fragment hits were able to displace PD-1 with 14 hits as score 2 and 22 hits as score 1 
(Appendix B). Increasing the fragment concentration resulted in higher percent rescue. 
For example, VU0432747 was found to result in approximately 75% signal rescue at 2 mM 
concentration (Figure 4-14). 
4.2.7 PD-L1 Hit clusters and analog screening 
Fragment hits obtained in the screen were highly diverse and were clustered into 
18 distinct chemotypes (Appendix B). Observed ring systems included both 5-6 fused and 
5-6 linked ring systems (Clusters 1 – 4, 8, 9, 10, 11, 12). In addition, 6-6 linked ring systems 
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and 5-6 and 6-6 ring systems with a 1 atom linker were also highly prevalent (cluster 5 – 
6). Commonly observed modalities include thiazol rings, mono and disubstituted phenyl 
rings and sulfur-containing heterocycles. Each hit cluster is associated with a hit class 
 
Figure 4-13: PD-1 displacement assay by NMR spectroscopy 
A) HMQC of 15N PD-1. B) HMQC of 15N PD-1 and equal molar concentrations of unlabeled PD-L1 
C) HMQC of 15N PD-1, unlabeled PD-L1 and 4 mM of fragment hit. Rescue in signal intensity from 
C) compared to B) suggests PD-1 is partially displaced by fragment binding to PD-L1. 
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(class A – C) although there are exceptions in each case. For example, hit cluster 1 is 
primarily class A whereas hit cluster 4 is primarily class B. Certain hit clusters also tend to 
have higher V-scores compared to other clusters, suggesting certain hit clusters were 
stronger than others. 
PD-1 displacement scores appear to be dispersed over most hit clusters, although 
there are a few hit clusters with higher prevalence (cluster 4, 7 and 11). Notably, cluster 7 
is a strong hit cluster with high V-scores and PD-1 displacement scores. This cluster 
consists of substituted biphenyl fragments that are highly similar to BMS patented PD-L1 
inhibitors (Chapter 6). To further develop SAR trends a 400-compound analog screen was 
designed by substructure similarity searches of each fragment chemotype in the 
 
Figure 4-14: Percent rescue of PD-1 G90 with 2 mM VU0432747. 
15N HMQC PD-1 spectrum is broadened by the addition of unlabeled PD-L1 (red HMQC). Rescue of 
signal intensity by addition of 2 mM of VU0432747 (blue HMQC). Stronger signal intensity of blue 
peaks suggests VU0432747 displaces PD-L1 from PD-1 resulting in stronger signal intensity. Inset 
1D slice of the HMQC spectra shows rescue of signal intensity from G90 of PD-1. G90 peak 
intensity is broadened to baseline by the addition of 14N PD-L1 (red line) compared to 15N PD-1 
alone (green line). Addition of 2 mM of VU0432747 rescues approximately 75% of the signal 
intensity (blue line). Image adapted from Perry et al 2019.172 
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Vanderbilt High throughput Screening Facility. 70 class A hits were identified, 33 class B 
hits were identified, and 22 class C hits were identified. However, most analogs had weak 
V-scores (5 class A hits > 3, 13 class B hits > 3). 
4.2.8 Co-crystal structures of fragments bound to PD-L1 
Generating structural information of fragments bound to the protein is crucial to 
guide the structure-based design of more potent analogs. The most straightforward and 
quickest way to generate structural information is by X-ray crystallography. While apo PD-
L1 crystalizes easily in many different crystallization conditions, all attempts to soak 
fragments into apo crystals failed. Analysis of the crystal packing reveals that the PD-1 
binding site of PD-L1 is completely blocked in both the IgV and IgV-IgC constructs in 
multiple different space groups (Figure 4-15, teal sticks). Thus, co-crystallization methods 
were needed to obtain co-crystal structures of the fragments bound to PD-1 binding site. 
Co-crystallization protocols recommend using ligand concentrations that are up to 10 
times the Kd to saturate the protein for the highest chance of getting ligand bound to the 
protein.160 Because the binding affinity of the fragment hits were weak, many fragments 
were not expected to reach saturation levels (estimated to be > 10 mM) due to limited 
solubility. For this reason, an emphasis was placed on fragments with the highest 
solubility to increase the chances of getting a bound structure. Attempts to co-crystallize 
PD-L1 in the presence of fragments near their respective solubility limit using IgV-IgC, IgV-
6His and IgV-6His-H140E constructs were all unsuccessful despite screening numerous 
protein crystallization kits containing a diverse set of conditions and different co-
crystallization and seeding methods.  
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It was evident that the crystal packing mechanism of PD-L1 was limiting our 
success in generating co-crystal structures. A series of mutants were designed were 
designed that would alter the crystal packing preventing PD-L1 from crystalizing with the 
PD-1 binding site blocked. Mutations were carefully designed to not interfere with the PD-
1 binding site where our fragments were predicted to bind. Notably, V76 was found to 
make crystal contacts and was in a loop region next to the PD-1 site that may offer some 
flexibility (Figure 4-15). V76 was mutated to a threonine to slightly change the 
physicochemical properties of this residue that may influence crystal packing while 
maintaining the binding interactions with PD-1 and the fragments.  Concentrating dilute 
 
Figure 4-15: Crystal packing of unliganded PD-L1. 
Crystal packing of unliganded PD-L1. PD-1 binding site (teal) comes together in a head to toe 
arrangement blocking the predicted fragment binding site. Blowup of the crystal packing interface 
suggests residues on the neighboring loop (V76, A51 and H69) could be mutated to block this 
crystal packing to encourage other packing that may yield an open PD-1 binding site. 
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(30 µM) IgV-6His-V76T in the presence of a fragment at 2 – 4 mM concentration and 
screening a Hampton index HT screen resulted in crystal formation in new conditions (1.4 
K2HPO4, 0.56 NaAH2PO4). PD-L1 in these conditions co-crystalized as a homodimer in the 
asymmetric unit with a fragment bound at the interface of the two monomers with a 2:1 
stoichiometric ratio of PD-L1 to fragment (Figure 4-16). More than 80 of the best 
fragments were screened around these crystallization conditions using the V76T 
construct. In total 13 co-crystal structures were obtained (Table 4-2). Notably, crystal 
structures were obtained from mostly class B fragments with high V-scores and PD-1 
displacement scores (Table 2). These results suggest the peak broadening seen in HMQC 
spectra may be due to transient dimer formation in solution. 
All co-crystallized fragments bind to the same hydrophobic pocket on PD-L1 with 
similar binding poses. In the fragment co-crystal structures, M115 from both monomer A 
 
Figure 4-16: Co-crystal structures of fragments bound to PD-L1. 
Fragments co-crystalize to PD-L1 by formation of a PD-L1 homodimer with a fragment inserted at 
the interface of the two monomers. PD-L1 monomer A is shown in yellow surface and monomer B 
is shown as gray surface. Fragments are shown as sticks and overlaid from multiple crystal 
structures to highlight the similar binding orientation of each fragment. Image adapted from Perry 
et al 2019.172 
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and monomer B are in a downward position compared to an upward position in the PD-1 
co-crystal structure (Figure 4-17A). The positioning of M115 opens a shallow hydrophobic 
Table 4-2: Fragments that co-crystallized with PD-L1 
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channel on the surface of the beta sheet lined by the residues I54, Y56, M115, Y123, and 
A121 of each PD-L1 monomer (Figure 4-17B). In the dimer crystal structure, these 
residues on each monomer come together to form a cylinder-shaped hydrophobic pocket 
in which the fragments occupy. One end of the hydrophobic pocket is closed off from the 
solvent by the upward positioning of Y56 on monomer A (Figure 4-17). Y56 on monomer B 
remains in the downward position allowing the other side of the pocket to be solvent 
exposed. Indeed, many of the fragments protrude from the pocket from this opening 
(Figure 4-16).  
 
Figure 4-17: PD-L1 homodimer forms a hydrophobic pocket capable of binding small molecules. 
A) M115 and Y56 residue conformational changes form a narrow binding cleft between residues 
on the beta sheet. M115 of PD-L1 bound to PD-1 (green sticks) is flipped up compared to down in 
PD-L1 fragment structures (yellow and gray sticks). Y56 of monomer B of fragment bound PD-L1 
(yellow) is flipped up to form the back end of the hydrophobic pocket. B) electrostatic surface of 
one monomer in the PD-L1 co-crystal structure showing the hydrophobic region that comes 
together to form a cylinder-shaped hydrophobic pocket that binds fragments. C) Dimer interface 
highlighting the hydrophobic residues (sticks) that bind to fragment hits. 
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The residues that form this pocket are also critical for the hydrophobic 
interactions with PD-1 and thus rationalize the results obtained in the AIDA NMR assay 
(Figure 4-17B, orange circle). Specific interactions of the fragment with PD-L1 are mostly 
hydrophobic with a few examples forming hydrogen bonds to nearby residues. Specific 
interactions of VU0432747 with monomer A including face-to-edge π stacking interactions 
with AY56, π-alkyl interactions with AM115 and AA121 and water-mediated hydrogen 
bonding with AD122 and with the amide of AY123 (Figure 4-19). Additional interactions 
with monomer B include π-alkyl interactions with BA121, BM115 and BY56 and a σ-hole 
interaction with the amide carbonyl of BM115. (Figure 4-19).  
 
 
 
Figure 4-18: Fragments bind to PD-L1 at the PD-1 binding site. 
A) Fragments (yellow spheres) bind to the PD-1 binding site and compete with PD-1 binding. B) 
Fragments (green sticks) bind to the hydrophobic region of PD-L1 which is the core of the PD-1 
interaction to PD-L1 surrounded by electrostatic interactions (yellow dashed lines). This overlay 
suggests various opportunities to expand fragment hits with charged substitutions to mimic 
electrostatics interactions made by PD-1 to PD-L1 to increase the binding affinity. 
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4.2.9 Hit to lead optimization by structure-based design  
X-ray co-crystal structures of 14 fragments bound to PD-L1 allows for the rational 
design of analogs via structure-based design. With over 300 hits identified in the screen, 
 
Figure 4-19: Fragment binding to a PD-L1 dimer results in two binding poses.  
VU0432747 is shown bound to the PD-L1 homodimer. Specific interactions are shown for both 
monomer A (left, yellow cartoon and sticks) and monomer B (right, gray cartoon and sticks). 
Image adapted from Perry et al 2019.172 
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three lead series were selected by triaging hits by the V-scores, Kd values, PD-1 
displacement scores, co-crystal structures obtained, SAR tractability from the screen, 
expansion potential and synthetic feasibility (Figure 4-20). Series 1 focused on a hit series 
identified in the screen containing a methoxy substituted benzothiazole core linked to a 
3-pyridine ring (Cluster 1). Because a thiazole moiety appeared to be a prominent feature 
of the screen, series 2 focused on a thiazole containing 6-5 ring system (Cluster 1). Series 
3 focused on phenyl substituted thieno-pyrimidinone core (Cluster 4). 
 
Figure 4-20: Triage of fragment hits to 3 lead series for medicinal chemistry 
Fragments hits were triaged by V-scores, Kd values, PD-1 displacement assay results, co-crystal 
structures, SAR tractability from primary screen and analog screen, expansion potential and the 
synthetic feasibility of each series. Based on these filters, three series were chosen for medicinal 
chemistry optimization. 
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Series 1 was the only series that did not have an X-ray structure prior to medicinal 
chemistry effort. Because this was one of the stronger series identified in the screen, it 
was thought that a crystal structure could be obtained of a more potent analog. Docking 
models of Series 1 suggested that the methoxy group was pointed towards solvent. Using 
this binding pose, analogs were designed to utilize this binding pose to incorporate amino 
acids to increase the solubility of the fragment and potential form electrostatic 
interactions with neighboring charged residues. Strikingly, substitution of the methoxy 
group to hydrogen or hydroxyl resulted in compounds that no longer bound to PD-L1. 
These results suggest that methoxy is forming important contacts with the protein.  
While a co-crystal structure was unable to be generated for this lead series, a 
related fragment (VU0126711) was successfully co-crystalized shortly after chemistry 
support was initiated. Like previous co-crystal structures, the thiazole ring of VU0126711 
forms a sigma-hole interaction with the carbonyl of AI116. The crystal structure reveals 
that the 6-5 fused core backs into AY56 which is in contrast with the previously used 
docking model. Furthermore, this structure suggests that the methoxy of VU0410942 
points towards AY56 causing a steric clash. This could explain why crystal structures were 
unable to be obtained with VU0410942 as no crystal structures were obtained with AY56 
in another conformation. Using the core from VU0126711, the pyridine ring of 
VU0410942 is expected to point towards the S1 region of PD-L1 (Figure 4-21). 
Modifications and extensions from the pyridine ring were made to expand into this region 
to form electrostatic interactions. Removal of the nitrogen from the pyridine ring (benzyl) 
negated compound binding to PD-L1 and addition of other nitrogen atoms in the ring 
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decreased the binding affinity. Extensions with charged substituents also resulted in 
weaker binding. In total, more than 80 compounds were made for this series of 
compounds and none were able to significantly increase the binding affinity. Given these 
challenges, chemistry support for series 1 was discontinued. I would like to thank Dr. 
Jianwen Cui for his hard work in synthesizing series 1 compounds. 
 
Figure 4-21: Series 1 hit to lead optimization 
A) SAR table of modifications made to the methoxy and pyridine ring of VU0410942. B) Co-crystal 
structure of closely related analog VU0126711 rationalizes SAR observed from VU0410942. C) Co-
crystal structures suggests expansion opportunities to the S1 region of PD-L1. 
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Series 2 was focused on a phenyl-linked thiazole core. This series had 3 related co-
crystal structures to facilitate structure-based design (Figure 4-22). Fragment merging 
strategies and structure-guided design of the phenyl ring substitutions were utilized to 
optimize binding in the hydrophobic cleft and facilitate expansion towards the S3 regions 
(Figure 4-22). Additionally, extensions with many different functional groups from the 2-
position of the thiazole core were synthesized to expand towards the S1 region. Using 
molecular modeling, overlays of Series 1 and Series 2 suggested pyridine rings may be 
incorporated to series 1 to extend towards S1. Pyridine rings with differing linkers were 
synthesized but failed to show improvement in the binding affinity. In other attempts to 
extend to the S1 region to form hydrogen bonds with D26, 5 atom linkers were designed 
with charged amines. From this series, an acetamide containing analog was the best with 
a Kd of 2.6 mM. To further expand into S3, a handle to conjugate a series of amino acids 
were made off the 2 and 3 positions of the phenyl ring. However, substitutions off the 
phenyl ring did not bind. These results suggest that dimer formation for this series is 
important as these substitutions were predicted to clash with the formation of the dimer 
and point towards solvent. In total 120 compounds were made for this series, but the 
binding affinity was too weak (> 3 mM) to give reliable and tractable SAR. Due to these 
challenges, efforts on this series were also discontinued. I would like to thank Dr. Chris 
Tarr for his hard work synthesizing series 2 compounds. 
Series 3 focused on a phenyl-linked thienopyrimidinone core. This series had two 
examples with co-crystal structures and many opportunities for expansion. The medicinal 
chemist on this series, Dr. Jonathan Mills, first sought to increase the solubility of this 
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fragment and pick up nearby electrostatic interactions by adding a short linker and 
carboxylic acid from the carbonyl that could be functionalized to include a series of amino 
acids. When this analog was tested by NMR, the peaks transitioned from class B 
 
Figure 4-22: Series 2 hit to lead optimization 
A) Co-crystal structure of VU0115538 bound to PD-L1 shown on monomer A. B) SAR table of 
analogs synthesized to expand into the S1 and S3 regions of PD-L1 (orange circles in A). N.B. 
indicates no binding. 
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(broadened) of the fragment to class A (shifted) (Figure 4-23). Based on the dimer crystal 
structure, the carboxylic acid is predicted to clash with monomer A (Figure 4-23). Thus, 
the change from peak broadening to peak shifting is likely explained by the inability to 
form a PD-L1 dimer with this analog. Indeed, the co-crystal structures of analogs of this 
fragment with substitutions that are predicted to clash with monomer A were unable to 
be obtained.  
The solubility of this compound was greatly improved over the fragment by the 
addition of a carboxylic acid allowing for concentrations above 3 mM for NMR titration 
experiments to more accurately determine Kd values of analogs. To maintain solubility 
and increase the binding affinity simultaneously, molecular modeling was used to design 
analogs that contained a carboxylic acid group close to R113 towards the S2 region. 
 
Figure 4-23: Series 3 analogs switch from peak broadening to peak shifting and prevent a 
protein dimer. 
Fragment is expected to bind to one monomer of PD-L1 prior to the second monomer binding to 
form a dimer. VU0432747 HMQC (left) has broadened peaks) an analog containing a carboxylic 
acid off the carbonyl position retains binding to PD-L1 as indicated by peak shifts (right) suggesting 
VU0432747 binds to monomer B and prevents formation of a protein dimer. 
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Consistent to modeling predictions, the proline-containing compound gave the best Kd 
(2.8 mM) due to the more rigid placement of the carboxylic acid in proximity to R113.  
 
Figure 4-24: Series 3 hit to lead optimization 
A) Co-crystal structure of VU0432747 bound to PD-L1 shown on monomer B. B) SAR table of 
analogs synthesized to expand into the S2, S1, and S4 regions of PD-L1 (black arrows in A). C) 
Fragment merging approach to add a methoxy to S4 pocket of PD-L1. Overlay of VU0432747 and 
VU0416396 suggests a methoxy substitution could be added to increase the binding affinity. 
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One of the most striking observations from the fragment crystal structures and 
related analogs was the diversity of phenyl substitutions that were tolerated in this 
pocket. A set of commonly observed phenyl substitutions in stronger fragments were 
designed to optimize the phenyl ring and provide a handle into S1. Of all substitutions 
tested, dioxane had the best Kd of 1.2 mM. Overlays of other crystal structures provided 
many opportunities for fragment merging approaches. VU0416396 overlaid with 
VU0432474 suggested a methoxy towards the small S4 pocket could be beneficial (Figure 
4-25C). Adding a methoxy to compound increased the binding affinity to 0.9 mM. 
Molecular modeling of the lead compound supports the predicted binding pose based on 
the rational design of this compound (Figure 4-25A). Further modeling studies suggest 
 
Figure 4-25: Molecular modeling of fragment analogs. 
A) Modeling using SeeSAR of lead compound binding to PD-L1. B) Modeling of a suggested 
compound to make to further expand into the S1 region of PD-L1. 
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additional interactions could be formed by expanding more into the S1 pocket (Figure 4-
25). However, no such molecules have been synthesized to date. I would like to thank 
Jonathan Mills for his hard work synthesizing series 3 compounds. 
4.2.10 High throughput screen of PD-L1 
While the optimization of fragment hits towards PD-L1 was disappointing, we 
were encouraged by the high hit rate suggesting that PD-L1 is druggable. With hopes of 
finding more elaborated molecules that may bind to PD-L1 with higher affinity than our 
fragments and serve as better starting points, we initiated a high throughput screen with 
assistance from the Vanderbilt High Throughput Screening Facility. Any HTS hit identified 
from the screen that bound to PD-L1 could complement the fragment hits by using linking 
or merging approaches to quickly gain more potent molecules. Indeed, other projects in 
the lab, namely WDR5, have benefited from having hits from both HTS and fragment 
screens. 
The Vanderbilt discovery collection of 100,000 compounds was screened using an 
FPA assay developed in our lab (chapter 5) using previously optimized assay conditions 
(15 nM PD-L1, 10 nM FITC labeled MCP probe) containing10 µM of the screening 
compound. To minimize potential fluorescent artifacts commonly observed in FPA assays, 
hit criteria were set to > 15% inhibition and +/- 20% of total fluorescence measurements 
relative to controls. In total, 106 hits were identified that fit the screening criteria (hit rate 
= 0.1%). However, measurements of the total fluorescence increased considerably when 
progressing hits to dose-response experiments suggesting interference from the 
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compounds. Given that the compound concentration was 1000x over the probe 
concentration, we hypothesized these compounds had inherent fluorescence properties 
at the FITC excitation and emission wavelengths (ex: 490 nm, em: 512) causing 
interference with anisotropy readings. To test this hypothesis, we conjugated an 
AlexaFluor 594 probe (ex: 594 em: 617) to the same macrocyclic peptide and re-screened 
the hits found by the FITC assay. None of the 106 hits reconfirmed by the AlexaFluor assay 
and orthogonal validation by 1H-15N HMQC NMR confirmed no binding to PD-L1. 
4.3 Conclusions and Discussion 
While modest improvements in the binding affinities have been made for series 3, 
the compounds were large (> 500 Da) and bind with low ligand efficiencies. Furthermore, 
additional crystal structures of analogs were unable to be obtained after extensive 
crystallization screening and additional changes to the protein construct. These 
challenges are thought to be caused by modifying the analogs to prevent dimerization of 
PD-L1. Because the binding of these fragments are weak, they fail to reach saturation of 
monomeric PD-L1 (10 x Kd = 9 mM) due to limited compound solubility at concentrations 
above 4 mM. Structural information of analogs binding to the target is highly important to 
continuously guide SAR. Modifications that are designed by modeling experiments often 
have unexpected binding poses or novel interactions resulting from protein binding 
dynamics not seen in previous structures or rigid docking models. Thus, only obtaining 
dimer structures of the initial fragment make the structure-guided design of monomeric 
binding analogs highly speculative.  
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Ideally, fragments would have been identified that bind to a nearby site and could 
be linked or merged for large gains in binding affinities. However, only one shifting 
pattern was observed in the HMQC spectra during screening. Of the 80+ fragments 
screened only 13 were able to be co-crystallized and all have similar binding poses. It is 
possible that other fragments have different binding poses that prevented co-
crystallization and thus our structures are biased towards one binding pose. Fragments 
that failed to co-crystallize were docked to PD-L1 using Induced Fit docking allowing for 
flexible side chains. However, the flat binding surface resulted in many different poses 
with similar binding energies and docking scores making it difficult to confidently suggest 
analogs to be synthesized. Given these challenges, efforts to continue optimizing the 
fragment hits to PD-L1 were discontinued.  
Encouraged by the high hit rate from the fragment screen, we initiated an HTS to 
find additional starting points. However, after screening 100,000 compounds using an FPA 
assay, we found no hits to follow up. The data presented in this chapter suggests that 
generating high-affinity molecules towards PD-L1 will be technically challenging. The lack 
of a deep pocket at the PD-L1 hot spot is likely why small molecules have weak binding 
interactions with the monomeric form of the protein. Fragments that were able to be co-
crystallized to PD-L1 formed PD-L1 homodimers around the fragments that create a larger 
hydrophobic pocket typically found in more druggable targets. However, attempts to 
optimize the binding to monomeric and dimeric PD-L1 resulted in only minor 
improvements.  
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4.4 Methods 
Cloning and site-directed mutagenesis 
 PD-L1 sequences were ligated into different plasmids containing N- and C-terminal 
fusion partners and purification tags (pET28b, pGEX6-1, pAT108 and pBG102). Restriction 
sites were added if donor vectors lacked desired restriction digest sites for proper ligation 
into destination vectors using site-directed mutagenesis. Mutants to PD-L1 sequences 
were made using protocols published by QuickChange II Site-Directed Mutagenesis Kit 
(Agilent). Primers were designed using Primer X (www.bioinformatics.org/primerx) to 
adhere to recommended primer design guidelines (25 to 45 bases in length, Tm > 78 °C, 
and GC content > 40%). PCR reactions were set up by addition of 50 ng of template DNA 
(plasmid), 125 ng forward primer, 125 ng reverse primer, 25 µL of 2X Phusion High-
Fidelity master mix (NEB) and water to a final volume of 50 µL. Thermocycler settings 
were: 98 °C initial denaturation, Step 1: 98 °C denature for 15 seconds. Step 2: 55 °C 
anneal for 1 minute. Step 3: Extend 72 °C for 3 minutes. Repeat steps 1 – 3 for 17 cycles. 
Extension at 98 °C for 6 minutes. Store at 4 °C. DPN1 (1 µL/50 µL reaction) was added to 
digest parent plasmid for 1 – 4 hours at room temperature. The digested PCR product was 
transformed to BL21 using electrocompetent DH5α E. coli cells (ThermoFisher). 
Transformed cells were plated on antibiotic plates overnight. Colonies were picked the 
next morning and grown in 12 mL overnight cultures. Minipreps were performed to 
extract plasmid DNA from each overnight culture (NEB). Extracted plasmids were 
sequenced (Genhunter) using a T7 promoter primer to check if the mutation was present. 
Successful mutagenesis clones were transformed to E. coli BL21 cells for expression. 
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Expression tests of PD-L1 constructs 
 Preliminary constructs of the extracellular portion of PD-L1 was cloned into the 
pET28b vector using NdeI and XhoI restriction sites to contain a thrombin cleavable N-
terminal 6His tag and transformed into E. coli DH5a cells. Transformed cells were grown 
on kanamycin plates overnight at 37 ˚C. Overnight cultures consisting of LB with 50 ug/mL 
kanamycin and picking colonies on the kanamycin treated plate. Small aliquots of media 
(10 mL of LB + 50 ug/mL Kan) were inoculated with 100 µL of overnight culture to 10 mL 
cultures for expression tests (1% inoculation rate). Samples were taken before and after 
IPTG induced expression of PD-L1. Post IPTG samples were lysed by sonication and 
centrifuged to separate soluble from insoluble fractions. SDS PAGE was run on each 
sample to determine the percentage of PD-L1 in the insoluble fraction. Consistent with 
previous reports, all PD-L1 constructs were expressed near 100% as insoluble inclusion 
bodies regardless of variation of expression temperature or IPTG concentrations. 
 New England Biolabs (NEB) has engineered strains of E. coli to have reducing 
cytosols allowing for the potential for proteins with disulfide bonds to be correctly folded 
after translation and expressed as soluble proteins. PD-L1 constructs containing 
chaperone protein fusion partners were transformed to two strains of the Shuffle Cells 
(C3026 and C3029). Expression tests were performed identically to previous expression 
tests in E. coli BL21. SDS PAGE was used to analyze the percentage of protein in the 
soluble fraction. 
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Protein expression and purification 
 For each construct, 500 mL of cell culture (LB media) was inoculated with 1% 
overnight culture and grown at 37 °C until cells reached an OD600 of 0.8 to 1. Cell pellets 
were resuspended in lysis buffer (50 mM Tris-HCl pH = 8.5, 150 mM NaCl, 20 mM DTT, 2 
mM EDTA and 1 mM PMSF) at 10 mL/g of cell pellet and lysed by homogenization at 4 °C 
(APV-2000, APV). Inclusion bodies were collected by centrifugation (10,000 x g for 20 
minutes). Inclusion bodies were washed using a series of washes containing lysis buffer 
and 2% Triton X-100, 1% Triton X-100, 0.5% Triton X-100 and 1.5 M NaCl wash steps 
(5,000 x g for 10 minutes per wash). Purified inclusion bodies were solubilized at 2 mg/mL 
in denaturing buffer (50 mM Tris-HCl pH = 8.5, 250 mM, 6M Guanidine HCl) for 4 hours at 
room temperature. The solubilized inclusion bodies were filtered through a 0.45 µm filter 
and refolded dropwise into refolding buffer (100 mM Tris pH = 8, 1 M arginine, 2 mM 
EDTA, 0.25 mM oxidized glutathione and 0.25 mM glutathione) at 4 °C overnight.1 The 
final protein concentration in the refolding buffer was 0.1 mg/mL. Refolded PD-L1 was 
dialyzed 3 times over 48 hours into dialysis buffer (10 mM Tris pH = 8, 20 mM NaCl). 
Buffer exchanged PD-L1 was concentrated using a stirred ultrafiltration cell with a 10 
MWCO filter (Amicon, Millipore). Constructs were concentrated until significant 
precipitation was seen (typically around 0.3 mg/mL for initial unstable constructs). 
Constructs with improved stability were concentrated to 0.5 - 1 mg/mL and loaded to a 
size exclusion column (Superdex75 26/60) pre-equilibrated with NMR buffer (50 mM 
Sodium Phosphate pH = 7, 25 mM NaCl) using an AKTA purifier. The elution profile from 
size exclusion was also used to evaluate the integrity of the construct by the elution of 
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monomeric protein verse soluble aggregation. 
Large scale protein production 
 The IgV domain of human PD-L1 (residues 18 – 134) was codon optimized and 
cloned into the pET28b vector using NcoI and NotI restriction sites to include a C-terminal 
6His tag (Genscript). The resulting vector was used to transform E. coli BL21 (DE3) GOLD 
cells (Strategene). Unlabeled PD-L1 for X-ray crystallography was expressed in LB media. 
Uniformly 15N labeled PD-L1 for NMR studies was expressed in M9 media containing 15N 
ammonium chloride (Cambridge Isotope Laboratories) as the sole nitrogen source. 
Inclusion body purification, refolding and further purification was the same protocol listed 
above. 
Fragment screen and titrations by NMR spectroscopy 
  NMR screening was performed at 30 °C using a Bruker Avance III 600 MHz 
spectrometer equipped with a 5 mm single-axis z-gradient cryoprobe and Bruker 
SampleJet sample changer. Screening samples (500 µL) contained 35 µM (0.5 mg/mL) of 
15N PD-L1 IgV-6His-H140E and fragment mixtures containing 400 µM of each fragment 
and 5% DMSO-d6. 1H,15N SOFAST-HMQC spectra were obtained using 26 scans (12 
minutes) and analyzed using Topspin (Bruker BioSpin). Deconvolution of hit mixtures was 
performed as a single fragment at 800 µM concentration. NMR titration experiments 
were performed by monitoring the change in 1H and 15N chemical shifts of 6-point 2-fold 
serial dilutions (3 mM, 1.5 mM, 0.75 mM, 0.375 mM, 0.188 mM, 0.093 mM). Kd 
measurements were calculated by fitting using an in-house script. Signal intensity of 
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ligand peaks in 1H NMR spectra (zgesgp) of each sample prior to HMQC acquisition was 
used to monitor ligand solubility. Data points with poor ligand solubility were excluded 
from analysis. 
NMR-based PD-1 displacement assay 
 NMR samples for the PD-1 displacement assay were made containing the same 
NMR buffer (50 mM NaPO4, 25 mM NaCl, 4% DMSO). PD-1 reference sample contained 
20 µM 15N labeled PD-1. PD-1 / PD-L1 reference sample contained 20 µM 15N labeled PD-1 
and 23 µM PD-L1 IgV-IgC. Test samples contained 20 µM 15N labeled PD-1, 23 µM PD-L1 
IgV-IgC and 2 mM fragment hits. 1H,15N SOFAST-HMQC spectra were obtained of all 
samples. Qualitative displacement scores were assigned by overlaying the HMQC spectra 
of test samples to the PD-1 / PD-L1 samples. Higher amounts signal intensity rescue was 
assigned a score of 2 while weak signal intensity was assigned a score of 1. No signal 
intensity was assigned a score of 0. 
X-ray crystallography 
 Unlabeled PD-L1 IgV-6His-H140E in X-ray buffer (10 mM Tris pH 8, 20 mM NaCl) 
was concentrated to 3 – 5 mg/mL (200 – 345 µM) and centrifuged at 13,000 rpm for 5 
minutes to remove precipitation. The Hampton Index HT screen was used to test 96 
diverse conditions for crystallization. Ligand-free crystals of PD-L1 IgV-6His-H140E were 
obtained in conditions containing 100 mM HEPES pH 7.5 and 2M ammonium sulfate 
overnight at 18 °C. Fragment bound crystals were generated by incubating PD-L1 IgV-6his-
V76T at 35 µM (0.5 mg/mL) with 2 – 4 mM of a fragment on ice for 3 hours in X-ray buffer. 
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Any precipitated fragment was removed by centrifugation (13,000 rpm for 5 minutes). 
The complex was concentrated to 200 µM (3 mg/mL) using 3 kDa MWCO amicon ultra- 
0.5 mL centrifugal filters (Millipore). Crystals of the fragment / PD-L1 complex were 
formed in conditions containing 0.056 M NaH2PO4, 1.344 M K2HPO4 within 48 hours at 18 
°C. All crystals were cryoprotected in mother liquor containing 20% glycerol prior to 
freezing in liquid nitrogen. Data were collected on the Life Sciences Collaborative Access 
Team (LS-CAT) beamlines at the Advanced Photon Source (APS), Argonne National 
Laboratory. Indexing, integration, and scaling were performed with HKL2000. The phases 
were determined by molecular replacement (Phaser-MR) using the PD-L1 IgV-6His 
construct (PDB code 5C35). The models were refined using phenix.refine and manual 
fitting the model to electron density using COOT. All figures were generated using PyMOL. 
Molecular modeling using SeeSAR 
 Co-crystal structures of fragments bound to either monomer were uploaded to 
SeeSAR. The binding pocket was defined to the residues surrounding the binding pocket. 
The compound was edited to explore binding possibilities in neighboring sub-pockets. 
Compounds were iteratively submitted for energy minimization and binding pose 
predictions. Results from SeeSAR modeling were used to design analogs of compounds 
and provide insight to the predicted binding pose of lead compounds. 
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Chapter 5 
Validation of literature reported PD-L1 inhibitors 
5.1 Introduction 
 Given the strong rationale for why small molecules would be advantageous over 
antibody therapies, there has been some interest in the field to develop such 
inhibitors.111, 161, 162 Indeed, inhibitors of the PD-1 / PD-L1 signaling pathway have been 
reported including small molecules, peptidomimetics and peptides.113, 163-165 
Peptidomimetic antagonists containing a central 1,3,4-oxa or thiadiazole cores and  1,2,4-
oxadiazole cores were discovered by researchers at Aurigene Ltd (Figure 5-1 A-B).113 
Examples of this series include amino acid substitutions from the 2 and 5 positions for 
1,3,4 oxadiazole series and 3 and 5 positions for the 1,2,4 oxadiazole series (Figure 5-1A-
B). A second peptidomimetic series containing dipeptides conjugated by a urea unit were 
 
Figure 5-1: Aurigene reported peptidomimetic inhibitors of the PD-1 signaling pathway 
Patented peptidomimetic inhibitors by Aurgine containing a 1,3,4-oxa or thiadiazole core (A), a 
1,2,4 oxadiazole core (B) and dipeptide conjugated by a urea unit (C). Image adapted from 
Zarganes-Tzitzikas et al 2017. 111 
 
A) B) C)
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also reported (Figure 5-1C). Aurigene has also disclosed multiple different peptides that 
range from 7 – 30 amino acids and have homology to portions of PD-1 sequence critical 
for the PD-L1 interaction.164 All Aurigene compounds are reported to have activity in a 
mouse splenocyte rescue assay that is dependent on the PD-1 signaling pathway. This 
assay monitors the inhibition T cell proliferation by addition of soluble mouse PD-L1 and 
CFSE dye that covalently binds to proliferating cells. Addition of compounds that inhibit 
the PD-1 / PD-L1 interaction results in a rescue in splenocyte proliferation. These reported 
compounds have reported rescue values ranging from 47 to 93% in this assay.113   
 Bristol-Myers Squibb (BMS) have also disclosed small molecule and peptide-based 
antagonists of the PD-1 pathway. The disclosed small molecule scaffold consists of a 
mono-ortho substituted biphenyl 3-phenoxymethyl core (Figure 5-2).163 These 
compounds have low nanomolar IC50 values in a homogenous time-resolved fluorescence 
 
Figure 5-2: BMS reported small molecule inhibitors of PD-L1 
Mono-ortho substituted biphenyl 3-phenoxymethyl core of small molecule inhibitors patented by 
BMS with examples given below (BMS-8, BMS-37 and BMS-230). These molecules were found to 
have < 100 nM IC50 values in a HTRF assay. Image adapted by Zarganes-Tzitziaks et al. 2017. 111 
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assay (HTRF) binding assay using Ig-tagged PD-1 and 6-His tagged PD-L1. However, no 
further in vitro or in vivo assays have been disclosed to support the biological activity of 
these molecules. Macrocyclic peptides MCP that target the PD-1 signaling pathway have 
also been disclosed by BMS.165 These peptides are divided into 3 main series containing 
14, 13 or 12 residue macrocycles and have low nanomolar affinity in both HRTF assays 
and nanomolar EC50 values in a variety of different cell-based assays (Figure 5-3). In this 
chapter, I discuss our efforts to validate these disclosed molecules and utilize structural 
information of these compounds to further develop our fragment hits into novel PD-L1 
inhibitors.  
5.2 Results 
5.2.1 Validation of Aurigene compounds 
 To validate these reported molecules, examples from each class were selected 
based on their reported activity and by the synthetic feasibility. Aurigene compounds 
were synthesized by Chris Tarr and Jianwen Cui. BMS small molecules were synthesized 
 
Figure 5-3: BMS reported macrocyclic peptides inhibitors of PD-L1 
Three series of macrocyclic peptides patented by BMS. Series is divided by the number of amino 
acids in the macrocycle Peptide 57 contains 14, peptide-71 contains 13 and peptide 99 contains 
12. Image adapted from Zarganes-Tzitziaks et al. 2017. 111 
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by Viva Biotech and the BMS macrocyclic peptide was synthesized by Plamen Christov of 
the Vanderbilt synthesis core. These compounds were first tested for direct binding to 
either PD-1 or PD-L1 by monitoring chemical shift changes in 1H-15N HMQC spectra.  
 Surprisingly, none of the peptidomimetics or peptides reported by Aurigene 
bound to either human PD-1 or human PD-L1 (Table 5-1). This result is consistent with 
Table 5-1: Synthesized PD-1/L1 inhibitors reported in the patent literature. 
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other reports that tested molecules in this series for binding to PD-1 and PD-L1115. One 
explanation to this discrepancy is that these molecules are specific for mouse PD-1 / PD-
L1 interaction as the assay used to report the activity of these molecules utilizes mouse 
splenocytes expressing mouse PD-1 with the addition of mouse PD-L1 to dampen the 
proliferation. While mouse and human PD-1 / PD-L1 proteins have high homology, crystal 
structures have revealed distinct binding modes between species that would have 
implications in small molecule binding.112 However, we have not tested this possibility by 
testing these compounds against mouse PD-1 or PD-L1. Notably, Aurigene recently 
partnered with Curis to initiate the first phase 1 clinical trial in humans with an orally 
available checkpoint inhibitor CA-170. CA-170 is claimed to be a dual antagonist of PD-L1 
and VISTA checkpoints, however, no direct binding studies to either protein has been 
disclosed. Thus, the precise mechanism of action of these compounds remains unclear. 
5.2.2 Validation of the BMS macrocyclic peptide 
 One MCP example was synthesized with the addition of an extra lysine residue as 
a synthetic handle to attach a fluorescent tag to facilitate biochemical assay development. 
The MCP causes large chemical shifts in PD-L1 HMQC spectra and has slow exchange peak 
broadening kinetics in NMR titrations suggesting the binding affinity of the peptide to be 
in the nanomolar range (Figure 5-4). X-ray structures of the MCP bound to PD-L1 were 
obtained to identify the binding site on PD-L1. Indeed, the MCP binds to the PD-1 binding 
site on PD-L1 (Figure 5-4 C) making this peptide an ideal probe molecule for assay 
development purposes. Conjugation of a FTIC probe at the extra lysine was used for the 
development of a high throughput fluorescence polarization anisotropy (FPA) assay to 
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rapidly assess the binding affinity of molecules made for this project.  
Using saturation binding experiments, the Kd of the FITC-labeled MCP probe to PD-
L1 was determined to be 2 nM (Figure 5-5B). The PD-L1 concentration and probe 
concentration was varied to obtain to the largest anisotropy window for optimal assay 
performance for a competition-based assay (Figure 5-5 C). The optimum buffer conditions 
 
Figure 5-4: BMS macrocyclic peptide inhibitors bind to PD-L1 at the PD-1 binding site. 
A) 2D structure of the BMS macrocyclic peptide synthesized with an addition lysine residue (left). 
B) 1H-15N HMQC spectra of 30 µM IgV-6His-H140E alone (blue) and 30 µM IgV-6His-H140E with 
100 µM of the peptide (red). Large chemical shift changes are indicative of binding. No chemical 
shifts changes were observed for HMQC spectra of PD-1 with the peptide (not shown).  C) X-ray 
structure of MCP bound to PD-L1 (gray surface). MCP (yellow sticks) binds to the PD-1 binding site 
(orange surface) shown by an overlay of PD-1 (teal cartoon) bound to PD-L1. 
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for this assay were found to be 1X PBS pH = 7.4, 0.05% Pluronic F-68 and 5% DMSO. The Ki 
of the unlabeled MCP in these conditions was found to be 29 nM. The optimized assay 
was found to be highly reproducible between days and multiple freeze-thaws of proteins. 
Due to the high affinity of the FITC-conjugated MCP, this probe molecule was 
given to our collaborator Dr. Young Kim to test for in vivo efficacy. Dr. Kim tested this 
peptide in established protocols for testing anti-PD-1 antibodies in combination with anti-
tumor vaccines developed in his lab.166, 167 Dr. Kim’s research focuses on the combinations 
 
Figure 5-5: Biochemical assay development using a FITC-labeled macrocyclic peptide 
A) 2D structure of the macrocyclic peptide with a FITC tag conjugated to the additional lysine 
residue. B) Saturation binding experiments to determine the Kd of the probe to PD-L1. PD-L1 was 
titrated from 1 μM to 0.5 μM in the presence of 10 nM FITC probe. The Kd of the probe was 
determined to be 2 nM. C) Example of the optimized FPA competition assay using increasing 
concentrations of the unlabeled MCP. Red and green lines are control wells setting the upper and 
lower limits of the assay containing only probe and protein (red line) and only protein (green line). 
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of checkpoint inhibitors with anti-cancer vaccines, namely GVAX vaccines. GVAX vaccines 
are composed of irradiated tumor cells that have been genetically modified to secrete 
stimulatory cytokines that enhance dendritic cells activity.168 Importantly, these vaccines 
have been shown to be synergistic with anti-PD-1/L1 therapy.169 Dr. Kim’s research has 
been focused on enhancing the activity of GVAX vaccines by the development of TEGVAX 
vaccines that also express multiple TLR agonists to further support activation to APCs.166  
Dr. Kim’s research lab tested the BMS MCP molecule in combination with GVAX in 
an in vivo assay using B16 melanoma mouse models. Consistent with previous reports, 
anti-PD-L1 and GVAX combinations were more effective than either therapy alone (Figure 
 
Figure 5-6: BMS macrocyclic peptide has comparable activity to anti-PD-1 in vivo 
Measured tumor volume from a B16 melanoma mouse model treated with anti-PD-L1 (light blue), 
GVAX vaccine (yellow), combination of MCP and GVAX (gray), combination of anti-PD-L1 and 
GVAX (orange) and anti-PD-L1 and TEGVAX (blue). Data and figure generously provided by Dr. 
Young Kim. 
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5-6, light blue, yellow, and orange).166 Strikingly, the MCP PD-L1 compound in 
combination with GVAX had comparable anti-tumor performance compared to the anti-
PD-L1 and GVAX combination. These results are an exciting example for developing low 
molecular weight inhibitors with nanomolar affinity to PD-L1 that demonstrate equivalent 
in vivo efficacy to currently used therapeutic antibodies.  
5.2.3 Validation of BMS small molecule inhibitors  
 Three examples of the BMS small molecules were also synthesized and tested for 
binding by NMR. Like the MCP, all three of these molecules bind to PD-L1, but not PD-1. 
Interestingly, BMS small molecules cause significant peak broadening and shifting in 1H-
15N HMQC spectra suggesting that PD-L1 forms oligomers in solution resulting in signal 
broadening (Figure 5-7 A). Indeed, PD-L1 incubated with BMS compounds elutes as a 
dimer on size exclusion chromatography (Figure 5-7 B). Co-crystal structures obtained of 
BMS #3 reveal BMS molecules induce a PD-L1 homodimer with one copy of the molecule 
at the interface of the two monomers as seen in previous fragment crystal structures. 
Indeed, the conformation of residues at the binding site in both PD-L1 monomers are 
identical to those obtained of the 14 fragment co-crystal structures previously obtained 
(Figure 5-8). The binding poses of fragments and the BMS molecules are also highly 
similar (Figure 5-9). However, the more elaborated BMS small molecules extend out of 
the hydrophobic pocket and make additional interactions with both monomers. These 
interactions include pi-stacking with BY56 and hydrogen bonding interactions with AD122 
and with the carbonyl of AF19 (Figure 5-8). These interactions outside the core of the 
pocket likely contribute to the reported high affinity of these molecules compared to the 
114 
 
 
weak affinity of our fragment hits.  
 Because peak broadening in HMQC spectra prevented generating a Kd by NMR, 
these compounds were tested in the FPA assay developed using the FITC-labeled MCP 
probe. Surprisingly, none of these compounds were able to displace the MCP probe even 
 
Figure 5-7: BMS small molecule inhibitors bind to PD-L1 and form PD-L1 homodimers. 
A) 1H-15N HMQC spectra of 30 µM IgV-6His-H140E alone (blue) and 30 µM IgV-6His-H140E with 
200 µM of the BMS small molecule #3 (red). Peak broadening seen in red peaks suggest oligomers 
of PD-L1 causing larger complexes with slow tumbling rates. B) Elution profile of NMR samples 
from size exclusion indicate that PD-L1 elutes as a dimer when bound to BMS small molecule #3 
(orange line). 
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at the top concentration of 1.5 mM (150,000 times higher than the probe and protein 
concentration) (Figure 5-10). Interestingly, the anisotropy was found to increase at higher 
BMS compound concentrations which we attributed to fluorescence artifacts of the 
 
Figure 5-8: BMS compounds co-crystalize as a PD-L1 homodimer 
BMS small molecule #3 co-crystalizes as a PD-L1 homodimer with a compound at the interface of 
the two monomers. These structures are highly similar to the fragment obtained structures in 
Chapter 4. Interactions of the BMS compound #3 and each PD-L1 monomer are displayed. BMS 
compounds extend out of the dimer interface and form hydrogen bonding interactions with F19 
and D122 (yellow dotted lines). 
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compounds being used at higher concentrations (mM).170  
 The FPA results suggest that PD-L1 dimerization may be heavily influenced by 
protein concentrations. PD-L1 concentrations used for in vitro experiments including NMR 
and X-ray crystallography can range from 15 µM to greater than 300 µM which may favor 
protein dimerization. Conversely, PD-L1 concentration in the FPA is 15 nM. Low protein 
concentrations would be less amenable to PD-L1 dimerization and may suggest the 
binding affinity to PD-L1 as a monomer is too weak to see an effect. However, BMS 
reports these molecules to have nanomolar IC50 values in a HTRF assay in which PD-L1 is 
 
Figure 5-9: BMS small molecule and fragment structures have similar binding poses 
A) Overlay of the BMS compound #3 (yellow sticks) and VU0432747 (green sticks) in the PD-L1 
dimer interface. B) Highlighted residues that interact with BMS compound 3 have identical 
configurations in fragment bound structures. C) 2D structures of both compounds and the overlay 
show similarity between the core of the BMS compound and our fragment hit. These overlays 
suggest potential fragment analogs that may have increased binding affinity to PD-L1. 
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used in low nanomolar concentrations. It is not clear why there may be a discrepancy 
between the HTRF and FPA assay formats. 
 Assuming these BMS molecules had nanomolar IC50 values in a TR-FRET assay we 
hypothesized that these compounds should be active in a cellular assay. To test this 
possibility the BMS compounds were tested in a PD-1 / PD-L1 cell-based assay purchased 
from Promega (Figure 5-11 A). This assay consists of Jurkat T cells are engineered to 
express luciferase via TCR signaling and CHO cells engineering to express PD-L1 on the cell 
surface. If PD-L1 is bound to PD-1, luciferase expression is inhibited. If the PD-1 / PD-L1 
interaction is inhibited, TCR signaling causes luciferase expression. Luciferase activity is 
then measured by measuring luminescence after the addition of luciferase substrate. 
  A PD-1 mAB was used as a positive control and had an EC50 value of 0.83 µg/mL 
which is close to the reported 0.72 µg/mL for this assay (Figure 5-11B). High 
 
Figure 5-10: BMS compounds are not active in a PD-L1 FPA assay 
FPA competition assay using FITC-labeled MCP with titrated BMS compounds starting at 1.5 mM. 
No decrease in anisotropy suggests these compounds fail to displace the FITC labeled MCP probe. 
To aid in solubility assays containing both 5% and 10% DMSO were utilized. Increases in 
anisotropy for the last 3 points (1.5 mM, 0.75 mM and 0.375 mM) are due to fluorescence 
properties of small molecules at high concentrations. 
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concentrations of the BMS compound the µM range were used to account for any weak 
activity from the compound. However, the BMS compounds had no activity and were 
found to be toxic at concentrations above 10 µM (Figure 5-11C).  
 These results suggest that while these molecules may bind to soluble PD-L1 at 
higher protein concentrations used for structural biology type experiments (NMR and X-
ray), their ability to inhibit PD-L1 at lower protein concentrations (FPA assay and on the 
surface of cells) may not be as effective and further optimization of these compounds 
 
Figure 5-11: BMS small molecules are not active in PD-1 / PD-L1 cell-based assays 
PD-1 / PD-L1 cell based assay purchased from Promega. A) Assay principal. aAPC/CHO-K1 cells 
engineered to express PD-L1 bind to T cells engineered to express luciferase by TCR signaling. PD-
L1 bound to PD-1 inhibits luciferase expression and luminescence after addition of luciferase 
substrate. If PD-1/L1 inhibitors are present, TCR signaling induces expression of luciferase and 
luminescence is observed by luciferase substrates. B) Positive control assay using anti-PD-1 
antibody purchased from Promega. Anti-PD-1 titration shows a dose response in luminescence 
suggesting the inhibitor is inhibiting PD-1 signaling. EC50 values obtained from this inhibitor is 
close to reported values. Blue line is of negative control cell line of aAPC/CHO-K1 cells that do not 
express PD-L1. C) BMS compounds fail to increase luminescence suggesting these compounds fail 
to inhibit the PD-1/L1 interaction. Image adapted from Promega. 
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may be required. Furthermore, no evidence has been produced that a glycosylated and 
membrane-anchored PD-L1 can adapt the conformation of a homodimer on the surface 
of cells and may explain why these compounds are inactive in cellular assays. While we 
were initially interested in using our fragments as alternative scaffolds to the BMS 
molecules to incorporate the extensive SAR published in BMS patents to rapidly increase 
the potency of our fragments, we were not convinced that this was a viable strategy to 
develop an inhibitor that would be active in cellular assays and in vivo studies. 
5.2.4 Fragment incorporation to the BMS macrocyclic peptide 
 The crystal structure of the MCP bound to PD-L1 was used to study the 
interactions that result in high affinity binding (Figure 5-12). Phe1, Phe7, and Trp10 of the 
BMS MCP make hydrophobic contacts with PD-L1 at the PD-1 binding site (Figure 5-12, 
 
Figure 5-12: BMS MCP co-crystal structure reveals key hydrophobic and polar interactions 
2D-structure of the BMS MCP peptide color coded with data from the BMS patent of affinity loss 
when mutated to alanine (left). Co-crystal structure shows Phe1 and Phe7 to bind at the 
hydrophobic pocket of PD-L1. Mutations to either of these residues result in > 600 fold loss in 
affinity to PD-L1. Affinity loss from 2D structure is also color coded on the MCP in the crystal 
structure (Red = major loss, orange = moderate loss, blue = some loss). No data was provided by 
uncolored residues. 
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right). Backbone amides of Cys11 and Lue12 and carbonyl of Trp10 make electrostatic 
interactions with charged residues nearby the hydrophobic pocket. BMS reported 
extensive SAR in their patent including alanine scanning of most of the residues.165 
Substituting Phe1 or Phe7 for alanine resulted in 600-fold and greater than a 1000-fold 
loss in binding affinity, respectively (Figure 5-12, left). Norleucine3 and Val6 also make 
hydrophobic interactions with PD-L1 and lost significant affinity when mutated to alanine. 
Notably, Tyr11 forms important intramolecular interactions that stabilize the 
conformation of the peptide loses 110-fold when mutated to alanine.  
 Overlay with fragment co-crystal structures reveals that fragment hits overlay with 
Phe7 highlighting the importance of Phe7. Strikingly, the placement of Phe7 is in the exact 
location and orientation of phenyl rings from BMS compounds and multiple fragments 
(Figure 5-13). This structural information highlights the key hydrophobic interaction is at 
this phenyl binding site.  Given this structural similarity, fragments could be incorporated 
as a non-natural amino acid at Phe7 to further enhance the binding affinity and develop a 
novel MCP that could be outside the scope of BMS patents (Figure 5-13). Indeed, our lab 
has had success in merging fragment screening results into peptides to enhance the 
binding affinity in other projects, namely RPA.171 Molecular modeling was used to explore 
the possibility of incorporating the fragment hits into the MCP structure. It was evident 
that the neighboring Trp10 could clash with fragments and would need to be mutated to 
either alanine or histidine (Figure 5-13). Modeling experiments suggest that incorporation 
of VU0115538 has the best potential to avoid steric clashes with Trp10 substituted 
residue. VU0115538 also contains a vector to further expand into the S1 region to make 
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additional electrostatic interactions made by PD-1 (Figure 5-13). While Trp10 is expected 
to have major contributions to the binding affinity, mutations of Trp10 to Ala were not 
reported in the patent. To test the importance of Trp10 to the binding affinity an MCP 
with Ala10 was synthesized and tested in our FPA assay. Unfortunately, Ala10 MCP was 
found to be completely inactive in the FPA assay and no detectable binding by NMR 
suggesting this residue is required for binding to PD-L1. It is unknown if a fragment 
incorporated into the MCP that would occupy similar space as Trp10 would retain binding 
affinity, as a fragment synthesized peptide was never synthesized.  
 
 
Figure 5-13: Fragment incorporation strategy to macrocyclic peptide 
Overlay of VU0115538 with the BMS MCP show identical placement of Ph9 and the phenyl ring of 
the fragment. Trp10 (transparent) may clash with fragment incorporation. To incorporate the 
fragment into the peptide, Trp10 will be mutated to alanine and VU0115538 will be added to 
Phe7 as a non-natural amino acid.  
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5.2.5 Modification of the BMS macrocyclic peptide linker  
 An additional strategy to generate a novel MCP is to modify the linker portion of 
the peptide to be outside of the BMS patents. BMS claims S, SO, SO2, O, and CH2 linked 
macrocycles do not claim cyclized linkers (Figure 5-14).165 We utilized modeling tools to 
design a series of different cyclized linkers at this position. To test the feasibility of this 
approach, a cyclohexane linked peptide was synthesized and had a Ki in the FPA assay of 7 
µM, representing a 280-fold loss in affinity to PD-L1. Additional linkers that were designed 
and tested also resulted in significant loss in affinity. Closer analysis of the linker portion 
 
Figure 5-14: Modification of the linker portion of the macrocyclic peptide 
A) Macrocyclic peptide linker portion from the X-ray co-crystal structure (green sticks) and the 2D 
drawing of the linker and what is claimed by BMS patents. B) Modeling of a cyclohexane linker on 
the X-ray structure. C) 2D structure of the synthesized macrocyclic peptide with a cyclohexane 
linker (orange). This peptide had a 280-fold loss in binding affinity monitored by the FPA assay. 
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reveals a sigma hole interaction of the MCP linker sulfur atom and backbone carbonyl of 
D61 (Figure 5-15). Additionally, the synthetic route to make the MCP resulted in the 
amide of residue 13 to be removed. This amide group forms intermolecular hydrogen 
bonding that presumably stabilized the MCP conformation (Figure 5-15, red sticks). These 
results are consistent with other modifications made that may alter peptide confirmation, 
such as removing other N-methyl groups, that also resulted in a dramatic loss in affinity. 
These results suggest that the conformation of the peptide is critical for high binding 
affinity to PD-L1. 
5.2.6 Modeling of fragment analogs to mimic BMS macrocyclic peptide interactions 
 We also utilized the structure of the MCP to guide the structure-based design of 
fragment hits. As mentioned previously, the MCP makes three key hydrophobic contacts 
 
Figure 5-15: Macrocyclic peptide linker has inter and intra molecular interactions 
Removal of residues on the MCP results in the loss of a sigma hole interaction with D61 (green 
solid line and angle) and intramolecular hydrogen bond (green dashed line). Loss of these 
interactions can rationalize the loss of binding affinity with novel linker pieces. 
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at the hydrophobic pocket. Overlay with VU0432747 on monomer B suggests the 
thiophene moiety of the fragment hits overlays with the Phe7. Docking experiments 
VU0432747 analogs with indole substitutions to mimic Trp10 and an addition phenyl ring 
to mimic Phe1 suggested a small molecule containing these substitutions may be capable 
of mimicking the key hydrophobic contacts made by the peptide (Figure 5-16 A). 
However, these molecules are very hydrophobic which could result in solubility issues in 
our biochemical assay. Thus, further docking studies were performed to add either a 
carboxylic acid or primary amine moieties to form electrostatic interactions with either 
R125 or E58, respectively. Extensions from the indole and phenyl rings were designed to 
reach R125 or E58 to form hydrogen bonds to R125, E58, and Y56 (Figure 5-16 B). The 
 
Figure 5-16: Modeling of VU0432747 analogs that mimic hydrophobic interactions from the 
macrocyclic peptide. 
A) docking model of an indole and phenyl substituted analog of VU0432747 that mimetics 
hydrophobic interactions made by the macrocyclic peptide (purple sticks). B) Docking model of 
compound in A) but with solubilizing groups that form polar interactions with R125 and E58. 
Potential cyclization of this molecule to form a macrocycle is shown by orange shape. 
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addition of 3 and 4 atom linkers induced some flexibility to the molecule which increases 
the entropy. To account for the increase in entropy, many different linkers were designed 
to generate a macrocycle (Figure B, orange shape). With enhanced occupancy of the 
hydrophobic pocket and additional electrostatic interactions, these molecules are 
predicted to bind with low micromolar affinity based on binding energies predicted from 
Maestro. However, these molecules would need to be synthesized and tested in the FPA 
to validate the docking results. 
5.3 Conclusions and Discussion 
 Given the discouraging results obtained in optimizing fragment hits to PD-L1, we 
hoped to utilize structural information of other disclosed PD-L1 inhibitors to rapidly 
improve our lead molecules. Interestingly, the Aurgiene compounds did not bind to either 
PD-1 or PD-L1. BMS small molecules were found to bind to PD-L1 by inducing a PD-L1 
homodimer in solution. Co-crystal structures reveal a highly similar binding pose to the 
fragment hits identified of our screen. Compared to our fragment hits, the BMS small 
molecules appear to be more optimized molecules that retain the ability to form a PD-L1 
homodimer. However, we found that these molecules were inactive in our FPA assay and 
cellular assays suggesting that these molecules need further optimization to have cell 
activity and raises concern about the ability of PD-L1 to homodimerize when anchored on 
the surface of cells.  
 BMS macrocyclic peptides were found to bind to PD-L1 with high affinity. 
Importantly, the peptides bind to monomeric PD-L1 as evidence by both NMR and 
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crystallography. These molecules are active in cellular assays reported in BMS patents and 
active in vivo with results obtained from Dr. Young Kim’s lab. These exciting results 
prompted us to utilize structural information of the macrocyclic peptide to guide the 
design of a novel inhibitor. We utilized various strategies to mimic the MCP including the 
incorporation of a fragment to the MCP structure, modifying the linker portion of the 
MCP, and designing fragment analogs to mimic key interactions with PD-L1. However, we 
found that even minor changes to the peptide resulted in dramatic losses of binding 
affinity. Due to this sensitivity of the MCP, we found it exceedingly difficult to design 
analogs that differ from patent-protected molecules and retained nanomolar binding 
affinity to PD-L1.  
5.4 Methods 
Binding of reported compounds 
 Binding of synthesized compounds to was tested by NMR with samples containing 
30 μM 15N PD-L1 IgV-6His-H140E and 200 μM BMS compounds in NMR buffer (50 mM 
NaPO4 pH = 7, 25 mM NaCl and 4% DMSO). Size exclusion was run using 200 μL of the 
NMR samples injected to a Superdex 75 10/300 GL column. The predicted molecular 
weight of elution peaks from size exclusion was calculated using the calibration curve 
reported in the user manual of the Superdex 75 column.  
X-ray crystallography of BMS small molecule and MCP 
 BMS #3 bound crystals were generated by incubating PD-L1 IgV-6his-V76T at 35 
µM (0.5 mg/mL) in X-ray buffer (10 mM Tris pH 8, 20 mM NaCl) with 1 mM of BMS #3 on 
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ice for 3 hours. The complex was concentrated to 200 µM (3 mg/mL) using 3 kDa MWCO 
amicon ultra- 0.5 mL centrifugal filters (Millipore). Crystals were obtained in conditions 
containing 29% PEG4000, 0.28 M NaCl, 0.01 M Tris pH = 8.5 within 48 hours at 18 °C. The 
macrocyclic peptide was incubated with 35µM PD-L1 IgV-6his-V76T,H140E and 200 µM 
peptide. The complex was concentrated to 200 µM (3 mg/mL) and screened against the 
Hampton Index HT screen. Crystals of the PD-L1 macrocyclic peptide was obtained in 3.5 
M sodium formate within 48 hours at 18 °C. 
 All crystals were cryoprotected in mother liquor containing 20% glycerol prior to 
freezing in liquid nitrogen. Data were collected on the Life Sciences Collaborative Access 
Team (LS-CAT) beamlines at the Advanced Photon Source (APS), Argonne National 
Laboratory. Indexing, integration, and scaling were performed with HKL2000. The phases 
were determined by molecular replacement (Phaser-MR) using the PD-L1 IgV-6His 
construct (PDB code 5C35). The models were refined using phenix.refine and manual 
fitting the model to electron density using COOT. All figures were generated using PyMOL. 
Cell assay methods 
 The PD-1/PD-L1 blockade Bioassay kit (J1250) was ordered from Promega. In 
addition to the kit positive and negative controls containing anti-PD-1 mAB (Cat.# J1201) 
and PD-L1 negative cells (Cat.# J1191), respectively. The assay was run according to the 
protocol using the recommended dose response (9-point curve, top concentration = 50 
μg/mL, 2.5-fold dilution) for the anti-PD-1 mAB. The BMS small molecule dose response 
consisted of a 9 point curve with a top concentration of 10 μM with a 2 fold dilution. 
128 
 
 
Concentrations past 10 μM of BMS #3 were toxic to the cells.  
FPA assay methods 
 Saturation binding experiments for the BMS MCP consisted of a 12-point, 2-fold 
serial dilution of PD-L1 IgV-IgC-6his produced by HEK293 cells with a starting 
concentration of 1 µM. The assay buffer consisted of 1X PBS pH 7.4, 0.05% F-68 Pluronic 
and 5% DMSO. To run the assay 25 μL of assay buffer was added to a black solid 
polystyrene 384 well plate. Next, 12.5 μL of 4X protein in assay buffer was added followed 
by 12.5 μL of 4X probe in assay buffer. Plates were spun at 300 rpm for 1 minute. The 
plate was incubated at room temperature for 15 minutes. Anisotropy was measured using 
485/20 528/20 wavelength filter. Graphs were plotted using Prism 5 Version 5.0b. 
 Optimized FPA competition assays using FITC-MCP were run using 15 nM PD-L1 
IgV-IgC-6his produced by HEK293 cells with 10 nM FITC-MCP in assay buffer (1X PBS pH = 
7.5, 0.05% F-68 Pluronic and 5% DMSO). Dose-response curves were generated using an 
11-point 2-fold dilution of untagged MCP starting at 25 μM. Control wells included wells 
with protein but no test compound and probe only wells (no protein) that determined the 
upper and lower anisotropy readings, respectively. The assay was performed by addition 
of 25 μL of 2X unlabeled MCP (or compound) to a black solid polystyrene 384 well plate 
followed up 12.5 μL of 4X PD-L1. The plate was spun at 300 rpm for 1 minute and 
incubated at room temperature for 15 minutes. Next, 12.5 μL of 4X probe was added to 
each well. Plates were spun again and incubated for 15 minutes at room temperature. 
Anisotropy was measured on a X machine with a 485/20 528/20 wavelength filter. Graphs 
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were plotted using Prism 5 Version 5.0b.  
Molecular modeling 
Maestro (Schrodinger) was used for all molecular modeling. The PD-L1 crystal structure 
bound to BMS MCP was prepared for modeling by adding missing side chains/residues, 
charged in pH 7 buffer, and energy minimized by the Protein Prep Wizard. A docking grid 
was generated around amino acids that bind to the MCP. All docked compounds were 
either drawn into maestro using the ligand sketch window or uploaded as SDF files. All 
ligands were prepared for docking using Ligprep. Compounds were docked using Glide 
rigid protein docking with normal settings and extra precision. Docking results were 
exported to Pymol to generate images. 
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Chapter 6 
General Conclusions and Future Outlook 
Immunotherapy offers an exciting therapeutic strategy to harness the power of the 
immune system to aggressively fight cancer. The development of mABs that target immune 
checkpoints to stimulate T cell activity towards cancer have been successful in a variety of cancer 
types and have revolutionized cancer care. However, the intrinsic properties of mABs may have 
negative implications when targeting immune checkpoint signaling pathways. These concerns 
include suboptimal tumor penetration, higher cost of production, potential immunogenicity, and 
prevalence of immune-related adverse events. An alternative therapeutic approach is to use small 
molecule inhibitors of immune checkpoint proteins. Indeed, small molecules have the potential to 
address many of these concerns with mABs. Some advantages of small molecule inhibitors include 
improved tumor penetration, potential oral bioavailability, lower cost of production and a longer 
shelf-life. Because the pharmaceutical and pharmacokinetic profile can be easily modulated, the 
design of inhibitors that are rapidly cleared from the body can minimize irAEs and allow for 
flexible dosing regimens. Despite these potential advantages, the development of small molecules 
that target immune checkpoints has lagged behind the development of mAbs. Given the limited 
reports of small molecules targeting CTLA-4, PD-1, or PD-L1 and the potential impact small 
molecules could have on immunotherapy, the goal of this dissertation was to utilize fragment-
based methods to assess the druggability of these targets and discover novel chemotypes that 
could serve as starting points for lead optimization towards potent inhibitors of these proteins. 
 In summary, CTLA-4 and PD-1 were separately screened against our fragment library. The 
CTLA-4 screen resulted in no hits. The PD-1 screen resulted in only 8 hits. The PD-1 hits have weak 
binding affinity and are expected to bind to the opposite side of PD-1 from the PD-L1 binding site. 
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Analogs were identified using substructure-similarity searches and screened against PD-1. 
However, none of the hits were found to have improved binding affinity to PD-1 or able to 
displace PD-L1. 
Unlike CTLA-4 and PD-1, the fragment screen of PD-L1 resulted in a diverse set of 
fragment hits (1.6% hit rate) that were clustered into 18 different chemotypes. While the binding 
affinities of these fragments were weak, many were found to displace PD-1 in an NMR-based 
displacement assay. In total, 14 co-crystal structures of fragments bound to a PD-L1 homodimer 
were determined. Fragments occupy a cylinder-shaped hydrophobic pocket formed at the 
interface of two PD-L1 monomers. PD-L1 homodimer structures presented unique challenges for 
structure-based design as each fragment had distinct binding poses on each PD-L1 monomer 
making it unclear which pose should be utilized for the design of analogs. Synthesized analogs 
were made to probe the correct binding pose by adding functional groups that clashed with the 
other protein monomer. Using these structures hundreds of compounds were modeled and 
synthesized to increase the binding affinity of these fragment hits. However, only minor 
improvements were made in each series. Furthermore, analogs that prevented PD-L1 
homodimers were unable to be co-crystallized. Without iterative structural information of 
compounds binding to PD-L1, structure-based design becomes challenging as the exact binding 
pose of more elaborate compounds becomes highly speculative.  
 During our work on this project, patents disclosing small molecules and peptides that 
target PD-L1 were published. One series of small molecule inhibitors of PD-L1 that have 
nanomolar IC50 values in a FRET assay was disclosed by BMS. Like the fragments, the BMS 
compounds also co-crystallized as a PD-L1 homodimer with the compound at the interface of the 
two monomers. Overlays of a BMS compound and fragments revealed that the methylated bi-
phenyl cores of these molecules have highly similar binding poses to PD-L1. However, BMS 
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compounds extend out of the dimer-induced hydrophobic pocket and make additional 
interactions with PD-L1. We found that the BMS compounds formed PD-L1 homodimers in 
solution at protein concentrations for NMR (30 µM). However, we found that these compounds 
were inactive in a cellular assay where PD-L1 is anchored to the membrane. Thus, it is unlikely 
that small molecules that induce PD-L1 homodimers will be a viable therapeutic strategy. 
 Large 16 amino acid macrocyclic peptides (MCP) that bind to PD-L1 with low nanomolar 
affinity were also reported by BMS. We found these peptides have comparable in vivo efficacy to 
anti-PD-L1 antibodies in a mouse model for human melanoma. Inspired by this result, we shifted 
chemistry support from optimizing fragments to generating macrocyclic peptides that target PD-
L1.  To understand how the MCP binds to PD-L1 with high affinity, a co-crystal structure of the 
MCP bound to PD-L1 was obtained. The MCP binds to the PD-1 binding site and occupies the same 
hydrophobic region of PD-L1 as our fragment hits. We employed two strategies to develop our 
own macrocyclic peptide outside the scope of the BMS patent. The first strategy was to 
incorporate our fragment hits into the MCP structure using structure-based design. The second 
strategy was to modify the linker portion of the peptide. However, we found that any 
modification to the peptide resulted in a dramatic loss of peptide binding affinity that ultimately 
discouraged us from synthesizing additional macrocycles. 
 Taken together, these results highlight the challenges of targeting immune checkpoints by 
small molecules. PD-1 and CTLA-4 are likely undruggable. We identified many different 
chemotypes that bind to PD-L1, but the optimization of these fragments to bind with high affinity 
will be difficult. These challenges result from the relatively flat binding surfaces and lack of 
hydrophobic pockets that favor small molecule binding. Indeed, the only co-crystal structures 
obtained for fragments and BMS compounds were of a PD-L1 homodimer. We suspect that PD-L1 
dimer formation was amenable due to relatively high concentrations of soluble protein used for 
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NMR and X-ray crystallography experiments. However, it remains to be seen if more optimized 
small molecules can induce PD-L1 homodimers on the surface of cells.  
 Small molecules that bind with high affinity to PD-L1 in a monomeric state would be 
preferred. However, our attempts to optimize fragment hits to bind to monomeric PD-L1 resulted 
in very weak binding affinities. Compared to the BMS macrocyclic peptide that binds to PD-L1 with 
high affinity, the fragments occupy a very small area on PD-L1. Thus, designing small molecules 
that would occupy more surface area while making additional hydrophobic and electrostatic 
interactions may be required to bind to PD-L1 with higher affinity. Thus, designing macrocycles 
based on these fragments could be an effective strategy moving forward. Ideally, we would have 
identified fragments that bind to an adjacent site on PD-L1 and could be linked to rapidly increase 
the affinity of our compounds. However, no such fragments were identified and the fragments 
that bound to the primary site were too weak to conduct a second site screen. Furthermore, we 
were unable to get co-crystal structures of larger analogs that might have suggested new 
strategies to expand our molecules. 
 In conclusion, these results are the first reported instances of using fragment-based 
methods to assess the druggablility and identify small molecule inhibitors of immune checkpoint 
proteins. While these proteins were predicted to be highly challenging targets for small molecules, 
we were able to successfully identify many fragments that bind to PD-L1 and displace PD-1. These 
fragments serve as an important starting point towards the design of small molecule inhibitors of 
PD-L1. Other drug discovery groups that are targeting PD-L1 with small molecules, peptides, or 
macrocycles could incorporate the fragment chemotypes identified from our screen to rapidly 
improve the binding or pharmaceutical properties of their lead compounds. These results also 
suggest fragment-based methods could be used to address the druggability of other immune 
checkpoint proteins. While other checkpoint proteins are also predicted to be undruggable 
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targets, these results suggest other checkpoint proteins could be druggable and should be 
validated experimentally by conducting fragment-based screens. 
  
  
135 
 
 
Appendix A. Hits from the fragment screen of PD-L1.  
  
136 
 
 
  
137 
 
 
  
138 
 
 
  
139 
 
 
  
140 
 
 
  
141 
 
 
  
142 
 
 
  
143 
 
 
  
144 
 
 
  
145 
 
 
  
146 
 
 
  
147 
 
 
148 
 
 
Appendix B: Hit clusters from PD-L1 screen with V-scores and PD-1 displacement scores: 
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